University of North Dakota

UND Scholarly Commons
Theses and Dissertations

Theses, Dissertations, and Senior Projects

January 2014

Goose-Derived Igy: A Potential Therapeutic
Antibody For The Treatment Of Infectious Disease
Ashley Louisa Fink

Follow this and additional works at: https://commons.und.edu/theses
Recommended Citation
Fink, Ashley Louisa, "Goose-Derived Igy: A Potential Therapeutic Antibody For The Treatment Of Infectious Disease" (2014). Theses
and Dissertations. 1650.
https://commons.und.edu/theses/1650

This Dissertation is brought to you for free and open access by the Theses, Dissertations, and Senior Projects at UND Scholarly Commons. It has been
accepted for inclusion in Theses and Dissertations by an authorized administrator of UND Scholarly Commons. For more information, please contact
zeineb.yousif@library.und.edu.

GOOSE-DERIVED IGY: A POTENTIAL THERAPEUTIC ANTIBODY FOR THE
TREATMENT OF INFECTIOUS DISEASE

By

Ashley Louisa Fink
Bachelor of Arts, Concordia College Moorhead

A Dissertation
Submitted to the Graduate Faculty
of the
University of North Dakota
in partial fulfillment of the requirements
for the degree of
Doctor of Philosophy

Grand Forks, North Dakota
December
2014

Copyright 2014 Ashley L. Fink
!

ii!

!

PERMISSION
Title

Goose-derived IgY: a potential therapeutic antibody for the treatment of
infectious disease

Department

Microbiology

Degree

Doctor of Philosophy

In presenting this dissertation in partial fulfillment of the requirements for a
graduate degree from the University of North Dakota, I agree that the library of this
University shall make it freely available for inspection. I further agree that permission for
extensive copying for scholarly purposes may be granted by the professor who supervised
my dissertation work or, in his absence, by the Chairperson of the department or the dean
of the School of Graduate Studies. It is understood that any copying or publication or
other use of this dissertation or part thereof for financial gain shall not be allowed without
my written permission. It is also understood that due recognition shall be given to me and
to the University of North Dakota in any scholarly use which may be made of any
material in my dissertation.

Ashley L. Fink
November 25, 2014

!

iv!

!

TABLE OF CONTENTS
LIST OF FIGURES…………………………………………………………………….vii
LIST OF TABLES…………………………………………………………………….viii
ACKNOWLEDGMENTS………………………………………………………………ix
ABSTRACT……………………………………………………………………………..x
CHAPTER
I.

INTRODUCTION……………………………………………………….1
Passive Immunization……………………………………………1
Avian IgY and the Avian Immune System………………………3
Structure and Function of IgY…………………………………...8
Physiochemical properties of IgY and IgYΔFc………………….9
Advantages of IgY for Passive Immunization………………….10
Oral Passive IgY Immunotherapy………………………………13
Other Therapeutic IgY…………………………………………..20
Summary………………………………………………………...22

II.

BIOAVAILABILITY OF ORAL IGY
Abstract………………………………………………………….23
Introduction……………………………………………………...24
Materials and Methods…………………………………………..28
Results and Discussion…………………………………………..31

!

v!

!

III.

IGY TREATMENT FOR MURINE CEREBRAL MALARIA
Abstract…………………………………………………………44
Introduction……………………………………………………..45
Materials and Methods………………………………………….49
Results…………………………………………………………..51
Discussion………………………………………………………58
Conclusions……………………………………………………..59

IV.

PASSIVE IMMUNIZATION OF IGY FOR THE TREATMENT OF
DENGUE VIRUS INFECTIONS
Abstract…………………………………………………………60
Introduction……………………………………………………..61
Materials and Methods………………………………………….75
Results…………………………………………………………..80
Discussion………………………………………………………92
Conclusions……………………………………………………..94

V. DISCUSSION……………………………………………………………….96
REFERENCES ………………………………………………………………………..100

!

vi!

!

LIST OF FIGURES
Figure

Page

1. Bioavailability of IgY………………………………………………………………..34
2. IgY detected in serum post oral administration……………………………………...35
3. Bioavailability of IgG………………………………………………………………..37
4. Bioavailability of IgY increases with multiple doses………………………………..39
5. Bioavailability of IgY increases in PBS pH 8.0……………………………………..41
6. Prolonged day to death following IgY treatment on days 2 and 5 p.i……………….53
7. Prolonged day to death following IgY treatment on days 2 and 4 p.i……………….55
8. Decreased parasitemia in mice treated with IgY on days 2 and 4 p.i. ………………57
9. Immunopathogenesis of severe dengue – an integrated model……………………...72
10. Anti-DENV2 IgY antibody titer in egg yolk……………………………………….82
11. Anti-DENV2 purified IgY neutralizes but does not enhance DENV2 …………….84
D2S10 in vitro
12. Therapeutic efficacy of anti-DENV2 IgY in vivo......................................................86
13. Identification of DENV2 NS3 epitopes…………………………………………….88
14. Identification of DENV2 E protein epitopes……………………………………….89
15. Identification of DENV2 PrM epitopes…………………………………………….90
16. Identification of DENV2 NS1 epitopes…………………………………………….91

!

vii!

!

LIST OF TABLES
Table

Page

1. Serum IgY and IgG concentrations (ng/mL)………………………………………33
2. Behavior of IgY against proteolytic enzymes……………………………………..43

!

viii!

!

ACKNOWLEDGMENTS
I would like to express my deepest gratitude to everyone who has provided
guidance and support throughout my graduate research career.
Foremost, I offer sincere appreciation to my advisor Dr. Bradley, for his
continued encouragement, support, and understanding. His genuine and steadfast
commitment to the advancement of science and young professionals is truly inspiring.
I would also like to thank the remaining members of my dissertation committee:
Dr. Nilles, Dr. Brissette, Dr. Carr, and Dr. Combs, for your presence and advice at my
research seminars and meetings. Additionally, I would like to recognize my past and
present colleagues at UND for their numerous discussions and instruction.
A special thank you to the members of the Bradley lab, especially Steve Adkins
who has offered unrelenting support and assistance in so many ways.
Finally, there is nothing worth achieving more than the love and support from my
family. I thank my parents for instilling and supporting my motivation to succeed in
whatever it may be. I also thank my husband Jacob; there is no way to truly express my
heartfelt appreciation for all that he has provided throughout our long graduate school
journey.

!

ix!

!

ABSTRACT
IgY, the predominate avian antibody isotype, has biochemical properties that
make it attractive for a human immunotherapy: IgY does not bind to mammalian Fc
receptor (FcR) or rheumatoid factor; IgY does not activate the mammalian complement;
and IgY has no heteroagglutinins. Anseriformes (waterfowl, e.g. ducks and geese)
produce 2 isoforms of IgY, full length IgY and alternatively spliced IgY, (IgYΔFc)
lacking the Fc region and a stable equivalent to mammalian F(ab')2 fragment, and the
predominate isoform following hyperimmunization. We, and others, have demonstrated
that egg-derived avian polyclonal antibodies are prophylactic or therapeutic for a variety
of different infectious agents including bacteria, viruses, and parasites.
Several routes of administration have been utilized for IgY, although the most
intriguing has been those that are administered orally. The targets for the successful oral
administrations have been associated with the gastrointestinal tract, other organ systems,
and systemic infections. However, bioavailability of orally administered IgY has not
been determined. As part of the research presented here, we administered purified goosederived IgY via oral gavage to mice and determined seroconversion. Oral IgY is
bioavailable and can be detected in the serum by 24 hrs. Multiple dosing and buffering to
pH 8.0 resulted in higher serum titers, with the buffered IgY preparations not detected
until 48 hrs. IgY was detectable up to 7 days post oral administration. Goose-derived IgY
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was relatively resistant to intestinal trypsin and chymotrypsin digestion but sensitive to
gastric pepsin digestion, as demonstrated by others with IgY from other avian sources.
This demonstration that orally administered IgY is bioavailable significantly increases the
potential applications of IgY therapy. Furthermore the ability to administer IgY orally
versus injection provides a novel and efficient means to treat disease worldwide.
In addition to determining the bioavailability of goose-derived IgY, we tested its
therapeutic potential in two unrelated disease models. One organism of interest for the
development of therapeutic IgY is dengue virus (DENV). At present, there are no antiviral agents or vaccines approved to treat dengue-induced disease. Dengue hemorrhagic
fever (DHF) and dengue shock syndrome (DSS), both disease manifestations originating
from dengue virus infection are severe and life threatening. These disease states are
mediated by serotype cross-reactive antibodies that facilitate antibody dependent
enhancement (ADE) by binding to viral antigens and then Fcγ receptors (FcγR) on
additional myeloid cells. In this study we hypothesized that avian IgY, which does not
interact with mammalian FcγR, would provide a novel therapy for DENV. Polyvalent
anti-DENV2 IgY was purified from eggs of DENV2-immunized geese and tested for its
ability to neutralize and enhance a DENV2 infection both in vitro and in vivo. Our data
suggests that DENV2 IgY is able to effectively neutralize DENV2 in the absence of
inducing ADE. DENV2-specific epitopes were determined in both the full length and
alternatively spliced (IgYΔFc) goose IgY populations and were used to develop affinity
purified DENV2 epitope specific antibodies.
The second organism used to test the therapeutic potential of IgY was
Plasmodium berghei, the causative agent of murine cerebral malaria. Human cerebral
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malaria is a severe manifestation resulting from the infection of Plasmodium falciparum.
Although there are successful antimalarial drugs on the market, there are increased
reports of isolated strains that are drug resistant, therefore highlighting the need for new
drug molecules or therapies to be used in combination therapy. Here we generated goosederived IgY that was specific for Plasmodium berghei, or the merozoite surface protein 1
(MSP-1) antigens, and determined their ability to treat cerebral malaria in a murine
model. Mice survived significantly longer and had decreased parasitemia when both
malaria specific IgY were administered together on days 2 and 4. These data suggest that
malaria specific IgY is a potential therapeutic candidate to be used in combination
therapy in order to prolong death and provide time for the combination drug to be
effective.
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CHAPTER I
INTRODUCTION
Passive immunization
Passive immunization refers to the transfer of antibodies from an immune donor
to a non-immune individual. Immunity is often artificially transferred by the injection of
antibodies or serum isolated from an immune human or animal. Passive immunity can
also occur naturally from the mother to the fetus during the placental or colostral transfer
of IgG or IgA. In contrast to active immunity, passive immunization has the ability to
provide rapid and immediate protection (1, 2). Passive immunization was first reveled by
Emil Adolf von Behring and his partner Kitasato Shibasaburo when they demonstrated
that blood serum from an infected animal could be injected into another animal to provide
immunity. Eventually the blood serum was named antitoxin and was used during the
early 1900s as a curative agent (3). In the following years, serum transfer was used to
treat many infectious diseases. Today, passive immunization of immunoglobulin isolated
from hyperimmune donors is used to treat numerous infectious diseases both
prophylactically and therapeutically (4, 5).
Most of the antibodies currently used in passive therapeutics are of human or
murine origin (4). In order to obtain sufficient human antibody titers for the use in
therapeutics, pre-screened volunteer donors are generally immunized with the
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antigen, and their plasma is then collected. Alternatively, convalescent sera is collected
from patients who have successfully recovered from an infectious disease (6). Although
human-derived antibodies are very effective treatment molecules, there are several
restrictions and limitations to obtaining them. For example, there are limitations on the
types of vaccines used, the number of immunizations permitted per individual, the
adjuvant used, and the amount of total plasma that can be collected (7). In addition, it is
unknown whether or not individual serum samples are further contaminated with virus or
other potential microbial species. Some of these limitations can be overcome by using
other animals as antibody sources.
Following the development of mouse hybridoma technology there has been an
increase in the number of therapeutic antibodies of murine origin. Although many of
these antibodies are currently being used in the clinic, they may not be ideal candidates.
Murine antibodies have a high potential to be immunogenic when administered to
humans. Often times the murine antibody is seen as a foreign antigen by the human
immune system and this triggers an immune response that can lead to the formation of
human anti-murine antibodies (HAMAs). HAMAs remain in the blood for a period of
time and can cause adverse reactions in patients, especially if the antibodies are reactivated during a secondary exposure. Unfortunately, the HAMA response can also lead
to antibody inactivation and clearance by the host immune system before the treatment
antibodies are able to provide protection. In order to overcome such challenges,
researchers designed a technique to genetically modify murine antibodies to make them
humanized. During this process the Fc portion of the murine antibody is replaced with the
Fc portion of a human antibody. Often this technique is used with monoclonal antibodies
!
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that are specific for a disease antigen. Humanized antibodies are currently being used to
treat several diseases, and there are even greater amounts that are in clinical trials (8).
Although humanized antibodies may offer sufficient protection, like the naturally
occurring human antibodies, they are highly susceptible to unwanted interactions with
conserved human proteins, and are laborious and costly to generate (9). In recent years
there has been an increased concentration on the development of avian-derived
therapeutic antibodies as an alternative to murine-derived passive immunotherapeutics,
whereas several studies have demonstrated their effectiveness in the absence of unwanted
host interactions.
Avian IgY and the Avian Immune System
Passive immunization with avian derived antibodies has emerged as an attractive
alternative approach to treat human and animal diseases. The avian immune system
differs from those of mammalian species specifically in the genes, molecules, cells and
organs it possesses, and also in functional mechanisms that it has evolved (10). Most of
the research that has been performed in order to better understand the avian immune
system has been done using a chicken model. Although chickens (galliformes) are closely
related to geese (anseriformes), it is important to understand that the chicken is just a
model and not all published research directly applies to all avian immune systems.
The avian immune system is comprised of both primary and secondary lymphoid
organs. The primary lymphoid organs include the thymus, bone marrow, and the Bursa of
Fabricus (BF). The secondary lymphoid organs are the spleen, harderian gland, germinal
centers, and other diffuse lymphoid tissues. The thymus is located in the neck along the
jugular vein and is where T lymphocytes both develop and mature. The thymus also
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includes a subpopulation of B lymphocytes. The bone marrow is the source of precursor
stem cells for both T and B cells that eventually migrate to either the thymus or the BF
where they are further differentiated. The BF is located on the dorsal surface of the cloaca
and consists of thousands of bursal follicles. The BF is the sole site of B cell maturation
and differentiation (10). In mature birds, the spleen is the major site of antigen processing
and antibody production. The harderian gland is located behind the eyeball within the
orbit and is the major secondary lymphoid organ within the head. This gland is comprised
of a large number of plasma cells with the majority of these cells being B cells.
Like the mammalian immune response, the avian immune response is divided into
an innate and adaptive response. The innate immune response has traditionally been
considered a non-specific response, however there is increasing evidence that there are
responses that are specific to different classes of pathogens (10). During the innate
response the first lines of defense are the physical and chemical barriers; the skin,
mucosal epithelium, and gastric secretions. The cellular components of the innate
immune response that confer specificity include the natural killer cells, macrophages, and
heterophils. Unlike mammals, the avian species do not have eosinophils, basophils, or
neutrophils (10). Heterophils are the predominate granulated leukocyte that are present
during the acute inflammatory response in galliformes (11). Heterophils are phagocytic
cells that both uptake foreign antigens via phagocytosis and release granules. They are
similar in function to neutrophils but have different granule components (11). Natural
killer cells are found in the spleen, peripheral blood, thymus, BF and intestine and are
cytotoxic cells that are important for completing antibody-dependent cellular cytotoxicity
(ADCC). Macrophages are phagocytic cells that serve as antigen presenting cells and
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bridge the innate and adaptive immune responses (10). Dendritic cells (DCs) are also a
population of very efficient antigen presenting cells that are found both in tissues that are
in contact with the external environment and in the bone marrow (12).
There are several cells in the avian innate immune response that have receptors
that will bind to foreign antigens and initiate the production of cytokines and chemokines.
These receptors are called pattern recognition receptors (PRRs) and they recognize
certain conserved molecules called pathogen associated molecular patterns (PAMPs).
Some of the most studied PRRs in the avian immune system are the toll like receptors
(TLRs) that recognize both cell surface and endocytic molecules. When TLRs recognize
PAMPs they initiate signaling pathways that can lead to the activation of NF-κB, type I
interferons (IFN) and the production of pro-inflammatory cytokines and chemokines
(10).
The adaptive immune response in avian species involves the targeted recognition
of specific molecular features on the surface of a pathogen, resulting in a series of events
intended to eliminate the pathogen and prevent future infection (13). Although protection
conferred by the innate response may be sufficient, the adaptive immune response is
generally required to clear pathogens and generate immunological memory (10).
Protection conferred during the adaptive immune response is mediated preferentially by
either a cell-mediated response or a humoral response, although non-exclusive (13). The
of presence of certain cytokines and chemokines, and sub sequential CD4+ T cell subset
(Th1/Th2) at the sight of inflammation is what determines the activation of the cellmediated or the humoral response, respectively. During an adaptive immune response
antigen presenting cells (APCs) present antigen within major histocompatibility (MHC)
!
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molecules to both T and B cells which recognize the peptide antigen. As a result of cell
mediated immunity, either CD4+ or CD8+ T cells are stimulated to proliferate and
become activated (10). CD8+ T cells, also known as cytotoxic T cells are involved in the
direct lysis of pathogen infected cells and tumor cells (13). CD4+ T cells have both
effector and regulatory functions; specifically they activate macrophages by secretion of
cytokines and stimulate B cell growth and differentiation.
The production of antibodies specific for foreign antigens is a result of the
activation of the humoral immune response. Antibodies are secreted by plasma B cells
and are found in both body fluids and tissue spaces. Present in the avian immune system
are three antibody isotypes, IgM, IgY, and IgA (14). Avian IgM, IgY, and IgA have been
identified as genetic homologs of mammalian IgM, IgG, and IgA (15, 16). IgM is
primarily found in the serum and egg white and is present on the surface of B cells (17).
IgM is generally the first antibody isotype secreted following an infection and it functions
to bind and activate the avian complement system. IgA is secreted continuously and is
found primarily in serum, bile, saliva, and at mucosal surfaces, but also found in the egg
white (17). IgY is the primary serum antibody but is also transferred from the serum to
the egg yolk during embryonic development. IgY is a homolog of mammalian IgG and to
some extent functions like both IgG and IgE, and has some characteristics of IgA. In
anseriformes there are two isoforms of IgY present, the full length IgY, and a smaller IgY
isoform formed by alternative splicing (IgYΔFc) that lacks the Fc antibody portion.
During egg formation, both IgY isoforms are passed from the blood to the egg yolk via
receptors that are specific for IgY translocation (18, 19). The amount of IgY that is
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transferred from the blood to the yolk is directly proportional to the serum concentration
(18).
The generation of antigenic diversity is remarkably different in the avian immune
system as compared to the mammalian immune system. In the avian system genetic
rearrangement contributes little diversity because both the heavy (H) and light (L) chain
loci consist of only one functional variable (V) and one functional junctional (J) gene.
Avians use three mechanisms to generate diversity in the antibody repertoire: somatic
gene hyper conversion, V-J flexible joining, and somatic point mutations (20-23). B cell
formation takes place in the BF during embryonic development and for a few weeks after
hatching. The BF is colonized in the embryo between days 8-14 of incubation by
immature progenitor cells that give rise to differentiated progenitors. The gene
rearrangement leading up to this takes place at both the H and L chain loci during the
early colonization process (24). All B cells use the same VL and JL segments (20) so little
diversity is gained during the VJL rearrangement process. Heavy chain rearrangement
also generates little diversity because there is only one VH and one JH and approximately
15 diversity (D) segments used (21). Subsequent V region diversity is generated by
somatic gene conversion events occurring on days 15-17 of incubation in which
sequences within the rearranged V region genes are replaced with sequences derived
from upstream pseudo-V region gene families (20, 21). These pseudogenes are located
upstream of both the VL and the VJ regions and are defined as pseudogenes because of
their lack in promoter sequences necessary for transcription, a truncated 5’ or 3’ coding
region, or lack in recombination signal sequences (20). Once the DNA is transferred from
pseudo V genes to the recombined VJL or VDJH regions of the immunoglobulin genes,
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the result is the production of mature B cells that migrate out of the BF and are competent
to form a functional humoral immune response (9). Approximately 5% of the B cells in a
newly hatched bird appear to be derived from rapidly dividing extrabursal precursors and
are potentially the source of peripheral B cells in older birds after bursal involution. In
mature birds B cells are often located in germinal centers within the spleen or other
mucosa associated lymphoid tissues. The activation of avian B cells to antibody secreting
B cells occurs via a similar mechanism to that in mammals. The avian B cell receptor of
germinal center B cells is modified by somatic hypermutation and gene conversion to
generate antibody diversity. Immunoglobulin class switching is also occurring
simultaneously in the avian germinal centers. In the terminal differentiation step
following antigen encounter, B cells first become plasmablasts and subsequently plasma
B cells. These cells are able to secrete antibody (IgM, IgA, and IgY) that is specific for
the antigen encountered (25).
Structure and Function of IgY
IgY is the primary immunoglobulin isotype in oviparous animals and is the
functional equivalent to mammalian IgG but also has the ability to sensitize tissues to
anaphylactic reactions (26). IgY is a low molecular weight serum antibody that contains
two heavy (H) and two light (L) chains and has a molecular mass of 180kDa, which is
larger than mammalian IgG (159kDa) (27, 28). The H chain of IgY possesses a variable
domain (VH), four constant domains (Cυ1-Cυ4) and lacks a hinge region. In contrast, the
H chain of IgG consists of a VH and three constant domains (Cγ1-Cγ3), where Cγ1 is
separated from Cγ2 by a hinge region (27). Also present in anseriform birds (waterfowl
e.g. ducks and geese) is a truncated (120kDa) form of IgY lacking Cυ3 and Cυ4. The
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truncated form of IgY coexists with the full length IgY and is the structural equivalent of
a F(ab’)2 fragment (28). Both full length IgY and IgYΔFc are generated by the same gene
but different pathways of mRNA processing (29, 30). It is important to distinguish the
difference in function between full length IgY and IgYΔFc. During the activation of the
immune response in avian species IgYΔFc is found later than full length IgY and is
unable to fix complement and sensitize tissues to anaphylaxis (31).
Physiochemical properties of IgY and IgYΔFc
IgY and IgYΔFc differ from mammalian IgG in their β-sheet content,
hydrophobicity, and isoelectric points. IgY has decreased β-sheet content specifically in
its constant domain (32) and thus a potentially more disordered conformation than IgG.
Full length IgY also has a larger Fc fragment than IgG and is therefore a more
hydrophobic molecule (33). When comparing the isoelectric point of IgG to IgY, IgY is
between 5.7-7.6, which is much lower than that of IgG (34).
IgY is a relatively stable molecule that is functional at a wide pH range. IgY is
functional between pH 4.0 -11.0 but changes if above or below (35, 36). IgY activity is
decreased in a pH 3.5 solution and is completely lost at pH 3.0 (32). IgY is also fairly
heat stable with minimal loss in activity at temperatures of 60-65°C and significant loss
in activity when heated to 70°C for at least 15 minutes (32, 35, 37). One way researchers
have overcome the temperature and pH limitations of IgY is to add additional sugars to
the antibody solution (38).
The stability of chicken IgY has also been tested in the presence of several
digestive enzymes, specifically pepsin, trypsin and chymotrypsin. The stability of IgY in
the presence of pepsin is highly pH dependent whereas activity remains high at a pH of 4
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but decreases significantly at pH 3.5 (39) IgY has moderate resistance to chymotrypsin
and trypsin and has very little loss in activity after an 8 hour incubation period in the
respective enzymes (39).
Advantages of IgY for Passive Immunotherapy
The use of IgY in therapeutics has many advantages over the traditional use of
IgG. One important advantage is the genetic background and phylogenetic distance that
distinguishes birds from mammals. IgY that is isolated from birds has a higher avidity for
mammalian antigens and has the ability to recognize different epitopes that may be nonimmunogenic in mammals (9, 27). There are data that suggest that when mammals and
chickens are immunized with the same antigen, the antibody repertoire that is present
post vaccination is different between the two animals (40, 41). In one study, chickens and
rabbits were both immunized with human papilloma virus type 16E7, and antibodies
were collected and used for epitope mapping with eight peptides. Antibodies isolated
from the chicken recognized all eight peptides, whereas rabbits only recognized two (40).
Furthermore it has been demonstrated that avian IgY that is specific for insulin receptors
in rats was able to inhibit insulin binding, but mammalian (rabbit) antibodies with the
same specificity could not (41). Another advantage that arises from the phylogenetic
distance of these two antibody reservoirs is the ability of IgY to be used as an antibody
against conserved mammalian proteins; proteins so highly conserved that it would
otherwise be impossible to use a mammalian antibody for treatment (42).
The ability of IgY to be easily isolated from the egg yolk poses another key
advantage to using IgY as an alternative to mammalian IgG. Eggs can be collected from
laying hens and the egg yolks used as a source of IgY. This is a rather rapid process that
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enables researchers to avoid serum collection while still maintaining high antibody
yields. The concentration of IgY present in the egg yolk of immunized birds depends on
the species, breed, age of the bird, and the antigen injected. Concentrations range from
60-150mg per chicken egg and 100-500mg per goose egg (43). An average laying hen
will produce upwards of 1000 to 2800mg of antibody per month, while geese will
produce even greater amounts. These concentrations are superior to what can be isolated
from the serum of rabbits or other animal sources (44). It has also been demonstrated that
older laying hens (2 years) will lay fewer eggs but will produce more IgY per egg yolk
(43, 45). It is important to note that the IgY isolated from these chicken eggs remained
stable and was functional over this extended period of time (43). The isolation technique
used for isolating IgY from egg yolks is also a fairly straightforward process that has
been exploited by many research groups. Briefly, the egg white is separated from the egg
yolk, and IgY is extracted using a series of centrifugation and precipitation steps and
finally purified using chromatography techniques. At present there are a number a
industrial processes set up for the collection and separation of eggs, making large scale
production of IgY a feasible option (27).
IgY has a number of different Fc mediated effector functions that suggest the use
of these antibodies would be better tolerated than mammalian antibodies. The Fc portion
of IgY functions different from IgG and therefore could prevent unwanted interactions
including the activation of complement, binding to rheumatoid factor (RF), HAMA, and
the binding to human and bacterial Fc receptors.
The purpose of the complement system is to initiate the recruitment of inflammatory
cells, which eventually leads to the clearance of the pathogen from the host. When
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mammalian antibodies are used for treatment, the Fc portion of the treatment antibody
has the ability to bind to self-antigens and activate complement. When complement is
activated under these conditions it can lead to unwanted inflammatory reactions due to
the production of anaphylatoxins C4a and C5a and antibody dependent cell-mediated
lysis. When anaphylatoxins are produced they have the ability to stimulate the release of
cytokines that can lead to the induction of shock in the patient (46, 47). The activation of
complement can also promote illness similar to serum sickness; immune complexes bind
to complement leading to the activation of leukocytes and even tissue damage. Although
IgY can activate complement in the avian system, its distinct structure prevents it from
being able to activate human complement (48). The Fc region of an antibody is composed
of different carbohydrates and the composition of this region is what determines its
ability to activate complement. It has been suggested that IgY is lacking the necessary Fc
carbohydrates that would allow it to promote activation (49). Therefore, the advantage of
using IgY would be its potential to prevent the aforementioned possible complications.
RF is an autoantibody that is generally associated with patients diagnosed with
rheumatoid arthritis, but not exclusively (50). RF will interact with the Fc portion of IgG
but will not interact with IgY. This is important because when RF antibodies bind to the
treatment antibodies, the treatment will likely be less effective or require a higher dosage
to be protective.
There is also evidence that suggests that IgY does not bind to the bacterial
proteins Staphylococcal protein A or Streptococcal protein G. Both of these proteins are
used during IgG affinity purification processes and other immunological bioassays.
Briefly, the bacterial protein is immobilized within a column matrix, the crude sample is
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passed through the column, and during this time the bacterial proteins will bind to the Fc
portion of the antibody in the sample. This becomes problematic if the assay is used to
purify IgG from a source containing treatment antibodies. There have been several
studies done to determine the binding capacity of the IgY Fc portion to these bacterial
antigens. Initially it was reported that chicken-derived IgY does not bind to
Staphylococcal protein A or Streptococcal protein G (51-54). However, recent reports
suggest that the reactivity of IgY may depend on the source. Specifically, Justi-Valliant et
al. demonstrated that when tested by direct ELISA, duck-derived IgY, but not chickenderived IgY, reacted with Staphylococcal protein A. It was also determined in this study
that neither duck-derived nor chicken-derived IgY interacted with Streptococcal protein
G. When the reactivity of IgY was compared to IgG, IgY proved to have much lower
reactivity to these bacterial proteins regardless of the source (55). Although these data
suggest that IgY may have the potential to bind to bacterial proteins, this binding is not
likely to be Fc mediated due to the structural differences between IgG, IgY, and IgYΔFc.
Oral Passive IgY Immunotherapy
Polyclonal avian IgY is currently being studied for its passive immunization
applications both in human and veterinary medicine. IgY has been effective against
several human pathogens and diseases both in vitro and in animal and clinical settings.
The therapeutic efficacy of IgY has been specifically demonstrated for a variety of
different infectious agents including bacteria, viruses, and parasites. Some of the most
prominent research studies suggesting the use of IgY for the treatment of disease will be
discussed below.
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Pseudomonas aeruginosa
One of the most successful clinical applications of IgY has been in the prevention
of Pseudomonas aeruginosa (P. aeruginosa) infections in cystic fibrosis patients. Cystic
fibrosis patients often present with repeated lung infections caused by P. aeruginosa,
which causes rapid deterioration in lung function and is the major cause of mortality in
these patients. In an attempt to clear the infection, these patients undergo antibiotic
treatment. If initial antibiotics fail to eradicate infection, the patient often becomes
chronically infected and will be subject to continual treatment with antibiotics. Antibiotic
treatment for prolong periods of time has detrimental effects to the host; specifically it
can lead to bacterial resistance, secondary infections, antibiotic toxicity, and the reduction
of normal flora (56-59).
There are ongoing clinical trials in cystic fibrosis patients using a mouth rinse
containing purified anti-P. aeruginosa IgY. Patients were asked to gargle the IgY mouth
rinse for two minutes and then swallow the rinse, after their last meal and brushed teeth.
Patients who were treated with the mouth rinse had an increased amount of time between
subsequent P. aeruginosa infections compared to the control group. Further study
indicated that those patients treated long term with the mouth rinse had fewer positive P.
aeruginosa cultures than the control group, and none of the patients in the experimental
group became chronically infected (60). Results of these experiments were similar in
another almost identical study researching the long term effects of an anti-Pseudomonas
IgY mouth rinse (61).
Nilsson et al. elucidated the mechanism by which IgY causes decreased
colonization by P. aeruginosa. These researchers determined that anti-P. aeruginosa
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binds to flagellin present on the surface of the bacteria. This binding may prevent the
bacteria from adhering to host proteins and reduce bacterial motility and thus decrease or
prevent P. aeruginosa infection (62).
Rotavirus
Rotavirus is viral pathogen that causes severe acute gastroenteritis specifically in
infants and children and the young of other mammalian and avian species, including
calves and piglets. At present, there are two orally administered vaccines that are
approved for use against human rotavirus and they are widely distributed and effective
throughout the United States. However, due to the lack of established health care in
developing countries, it has been difficult to institute an effective vaccination protocol
and therefore rotavirus induced diarrhea remains the cause of death for millions of
children (63). The need for a treatment alternative has fueled several researchers to assess
the potential of rotavirus specific IgY to be used as an oral passive immunization therapy.
Human trials have been done to test anti-rotavirus IgY in children suffering from
virally induced diarrhea. Specifically, children that had confirmed cases of virally
induced diarrhea were treated orally with anti-rotavirus IgY or naïve IgY and stool output
was determined. By day 4 post treatment, 74% of children treated with anti-rotavirus IgY
no longer had diarrhea whereas less than 50% of the control group no longer had diarrhea
(64). Another study was done using gnotobiotic piglets that were experimentally infected
with human rotavirus at 24 hours of age and treated twice a day for 9 days (days 3-12)
with cow milk supplemented with rotavirus specific IgY. Treatment with rotavirus
specific IgY dose dependently protected the piglets from diarrhea and significantly
reduced virus shedding (65).
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Bovine rotavirus is a common cause of diarrhea in neonatal calves typically
through 8 weeks of age (66). Bovine rotavirus in calves becomes a major issue for the
cattle industry because of financial loss due to a reduction in body weight and the
expense of treating the disease. The current treatment strategy is to vaccinate the mothers
and rely on passive antibody transfer from the mother to the newborn calf. Vaccination
has been somewhat successful, however it does not prevent virus infection. Passive
immunization with bovine rotavirus specific IgY has proven to be an attractive alternative
treatment (65, 66)
Vega et al. experimentally inoculated 2-day-old calves with bovine rotavirus and
then treated them with milk containing 6% bovine rotavirus immune egg yolk, or nonimmune control egg yolk twice a day for 14 days. In this study, 80% of the infected
calves that were fed the bovine rotavirus immune egg yolk were protected and the
antibodies could be detected in the feces at 21 days post infection (66).
Helicobacter pylori
Helicobacter pylori (H. pylori) is the causative agent of gastritis and gastric
ulcers. H. pylori produces several virulence factors but one of the most important for
bacterial colonization is the urease enzyme. Urease is able to hydrolyze urea into carbon
dioxide and ammonia to permit the bacteria to survive in the gastrointestinal tract (67).
Gastritis and ulcers are caused by the H. pylori induced disruption of the gut epithelium.
This infection is generally treated with antibiotics although treatment is not always
successful. Purified anti-H. pylori IgY has been shown to decrease bacterial adhesion,
growth, and urease activity in vitro and decrease H. pylori induced gastric mucosal injury
and inflammation in vivo (68). Patients suffering from H. pylori infections were also
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given a yogurt that contained 1% anti-urease IgY as well as Lactobacillus acidophilus
and Bifidobacterium species. The patients who drank the yogurt had suppressed H. pylori
infection compared to the control group (69). In vivo studies using mice have also been
exploited to test the efficacy of H. pylori antigen specific IgY treatment. In this study
mice were infected with H. pylori and the anti-Hp58 IgY was administered on day 1,
week 1, week 4, or week 12-post infection. When administered one week post infection
there was a significant difference in the degree of gastritis and a higher recovery rate
compared to the control group (70).
Streptococcus mutans
Streptococcus mutans (S. mutans) is one of many bacteria present in the mouth
that can cause infections, specifically dental carries. Most treatments are focused on
eliminating the bacterium or suppressing virulence factors. There have been several
studies using various forms of S. mutans IgY that provide evidence that IgY can be used
to treat these infections. Hatta et al. evaluated the efficacy of oral anti- S. mutans IgY
mouth rinse to prevent bacterial colonization. Those patients who gargled the mouth rinse
had a decreased level of S. mutans as well as a higher protection from dental carries (71).
In a randomized, double blind, placebo-controlled study, Nguyen et al. also reported that
anti-cell associated glucosyltransferase IgY could significantly suppress oral colonization
by salivary S. mutans (72). Cell-associated glucosyltransferase is essential for the
production of glucans by S. mutans and is an important virulence factor.
Salmonella
Salmonella enterica serovar Enteritidis (Salmonella ser. Enteritidis) and
Salmonella enterica serovar Typhimurium (Salmonella ser. Typhimurium) cause major
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outbreaks in humans but also in other animal species such as chickens. Salmonella
species have several virulence factors that are targets for the creation of passive
immunotherapies. One of the virulence factors targeted is the fimbria surface antigen of
Salmonella ser. Enteriditis. Fimbria is implicated in the bacterial adherence to the
mucosal epithelium of the host. Peralata et al. demonstrated protection with IgY specific
for the Salmonella ser. Enteriditis fimbria (SEF) 14. Briefly, SEF-14 specific IgY was
isolated from the egg yolk of immunized laying hens and given to mice that were infected
with Samonella ser. Enteriditis. Mice that were treated with the IgY had increased
survival rate compared to the control mice treated with naïve IgY. When given the
highest antibody titer the survival rate was 77%, the lowest titer survival rate was 59.3%
and the naïve IgY survival rate was only 32% (73). The SEF-14 IgY was also tested in
vitro using isolated murine small intestinal cells. In this experiment the SEF-14 IgY
decreased the adherence of Salmonella ser. Enteritidis to the small intestinal cells when
compared to the naïve IgY. These researchers suggest that although the mechanism of
protection is unknown, it is likely that the SEF-14 IgY is preventing initial attachment of
the bacteria to the cell surfaces (73).
Others have also done research with Salmonella specific IgY targeting the outer
membrane proteins (OMP) of the bacterium (74, 75). Yokoyama isolated IgY from
chickens that were immunized with OMP, lipopolysaccharide (LPS), and flagella from
either Salmonella ser. Enteritidis or Salmonella ser. Typhimurium. These three proteins
are associated with bacterial virulence. To test the efficacy of the antigen specific IgY,
mice were infected with either bacterial strain and then orally administered OMP,
flagella, or LPS specific IgY antibodies. Antibodies were administered three times a day
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for three days total. The mice that were infected with Salmonella ser. Enteritidis had a
80% survival rate with OMP IgY, 60% survival rate with the flagella IgY, 47% survival
rate with the LPS IgY, and 20% survival rate with the control naïve IgY (75). The mice
that were infected with Salmonella ser. Typhimurium had 40% survival rate with OMP
IgY, 30% survival rate with LPS IgY, 20% survival with the flagella IgY, and all control
naïve mice died (75). These research studies demonstrate that IgY specific for Salmonella
or Salmonella virulence factors has the potential to be used for the passive treatment of
human salmonellosis.
Escherichia coli
Enterotoxigenic Escherichia coli (ETEC) is an enteric bacterium that causes
severe diarrhea in both animals and humans. ETEC is one of the most frequent causes of
childhood diarrhea prevalent in developing countries. ETEC is also the cause of diarrhea
in newborn calves and in piglets. ETEC uses adhesion molecules to adhere to the small
intestine and secrete enterotoxins. These enterotoxins cause the increased secretion and
reduced absorption in the small intestine (76). ETEC is often treated through the use of
antimicrobial agents and thus finding alternative treatment options is necessary.
ETEC specific IgY has been used in research studies to determine its efficacy in
treating animals infected with the bacterium. Porcine ETEC fimbrial antigens K88, K99,
and 987P are associated with bacterial adhesion and therefore are good targets for the
production of IgY. IgY that was produced against these antigens showed to decrease
ETEC binding to porcine epithelial cells and intestinal mucus in vitro. When piglets were
treated with the antigen specific IgY, there were no adherent ETEC along the intestinal
epithelial surface (77).
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Other researchers have used freeze-dried K88 fimbiral antigen specific IgY to
treat piglets or neonatal pigs that were experimentally challenged with ETEC. These
antibodies were made into a powder and administered orally post infection at different
time points. K88 IgY was able to protect both the neonatal and 21 day weaned piglets
from ETEC induced diarrhea in just 24 hours post treatment. Piglets that were given
naïve IgY powder continued to have diarrhea and only 37.5% of them survived
(78).
Ikemori et al. has exploited the K99 pilus virulence factor to create K99 specific
IgY powder that can be administered in colostrum to newborn calves in order to protect
them from ETEC induced diarrhea. In this study the calves were challenged with ETEC
and then treated with either the K99 specific IgY or naïve IgY powder in milk. The
calves that received a high titer IgY treatment had only temporary diarrhea and did not
experience weight loss or dehydrateion, whereas the control group developed severe
diarrhea and died 3 days post challenge (79).
Oral therapeutic IgY summary
The aforementioned research studies represent a significant amount of evidence
for the efficacy of orally administered IgY to treat various diseases both contained within
the gastrointestinal (GI) tract and potentially within other organ systems. Despite this,
there are no published findings demonstrating the oral bioavailability of these antigen
specific IgY antibodies.
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Other therapeutic IgY
Venom IgY
In many parts of the world snakebites and bites from other venomous animals are
medical emergencies. According to the World Health Organization (WHO) report in
2007 on snakebites, there are about 5 million snakebite incidences resulting in 2.5 million
envenoming, and 125,000 deaths that occur annually (80). Envenomation is usually
performed using anti-venoms that are derived from horse sera. A deleterious outcome of
using horse sera anti-venoms is that they often contain large amounts of non-specific
horse proteins that can cause side effects such as serum sickness and anaphylactic shock
when used for treatment in patients (81-83). Several studies have examined the potential
of anti-venom IgY for envenomation in order to avoid the unwanted reactions between
the currently available anti-venoms and the human immune system.
One of the first demonstrations of IgY anti-venom was the purification of IgY
from the egg yolks of hens that were vaccinated with either Cortalid snake venom or
Leiurus quinquestiratus hebraeus scorpion venom. In this study the neutralizing potential
of the IgY was tested by mixing the anti-venom IgY with a lethal dose of each venom
and then injected into mice. All ten mice administered the anti-Cortalid IgY and 7 of the
8 mice administered the Leiurus quinquestiratus hebraeus IgY were alive at 24 hours
post infection. All but one of the control mice died by 24 hours post infection (84).
Several other studies have been done that also suggest the neutralizing potential of antivenom IgY is very high (85-87).
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West Nile Virus IgY
Past research in our lab has exploited geese as a source of IgY. Initial studies
aimed to determine if the serum from West Nile Virus (WNV) immune geese could
protect against WNV infection in geese. Geese were given immune serum prior to and
post WNV infection and mortality was assessed. Of the ~10,000 geese per group there
was a 65% reduction in mortality when serum was administered as a prophylactic and
62% reduction in mortality when administered as a treatment. These experiments were
repeated with purified anti-WNV IgY and similar results were observed. Purified antiWNV was also tested in WNV infected golden hamsters. All of the hamsters treated with
anti-WNV IgY survived and had viral titers of zero, compared to the sham treated
hamsters that had 100% mortality and 65% viral titer (Bradley et al., unpublished data).

Summary
As evidenced by the significant body of related research, passive immunization
with avian antibodies is an unconventional and appealing strategy for the treatment of
infectious diseases. The following chapters will describe the current research in our lab
focused on the bioavailability of goose-derived IgY, the ability of Plasmodium specific
IgY to treat murine cerebral malaria, and the epitope mapping and viral neutralization
capacity of anti-dengue virus IgY.
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CHAPTER II
BIOAVAILABILITY OF ORAL IGY
Abstract
Avian IgY exhibits biochemical properties that make it an attractive human
immunotherapeutic. Unlike mammalian IgG, IgY does not bind to mammalian Fc
receptor (FcR) or rheumatoid factor, does not activate mammalian complement, and has
no heteroagglutinins. The prophylactic and therapeutic efficacy of IgY has been
demonstrated for a variety of different infectious agents including bacteria, viruses, and
parasites. The targets for the successful oral administrations have been associated with
the gastrointestinal tract, other organ systems, and systemic infections. However,
bioavailability of orally administered goose-derived IgY has not been determined. In this
study we administered purified goose-derived IgY via oral gavage to mice and
determined seroconversion. Oral IgY is bioavailable and can be detected in the serum by
24 h. Multiple dosing or increasing the pH resulted in higher serum titers. IgY was
detectable up to 7 days post oral administration. Goose-derived IgY was relatively
resistant to intestinal trypsin and chymotrypsin digestion but sensitive to gastric pepsin
digestion, as previously demonstrated with IgY from other avian sources. This
demonstration that orally administered IgY is bioavailable significantly increases the
potential applications of IgY therapy. Furthermore the ability to administer IgY orally
provides a novel and efficient means to treat disease worldwide.
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Introduction
Immunoglobulins are well-established affinity molecules that have applications
ranging from biochemical analysis, diagnostics, and therapeutics. Mammalian
immunoglobulins are the most commonly used and have proven to be adequate for most
approaches. They are however highly susceptible to unwanted interactions with
conserved proteins and can promote unnecessary immune mediated pathologies.
Mammalian antibodies have the ability to activate the human complement system and
thus have the potential to reduce the binding capacity of the antibody to the target antigen
(88). Furthermore, when complement is activated the anaphylatoxins that are released,
C4a and C5a, have the ability to initiate unnecessary inflammatory reactions such as
stimulating the release of TNF-α. Another example is the binding of mammalian IgG to
the auto-antibody rheumatoid factor (RF). RF is found primarily in patients with
rheumatoid arthritis but is also found in a small percentage of healthy blood donors (50).
When IgG binds non-specifically to RF, the total IgG available to interact with the
disease antigen is decreased. These characteristics among others hamper the use of
mammalian or humanized immunoglobulins for use as therapeutics.
The development of unconventional methods to generate antibodies that are
suitable for use as therapeutics is an area of active research. Immunoglobulin Y (IgY) is
the major immunoglobulin in oviparous animals. Many distinct properties of this
antibody type allow it to overcome several of the limitations of the current mammalian
derived therapeutic antibodies (9). During egg formation, IgY is passed from the blood to
the egg yolk through receptors that are specific for IgY translocation (18, 19). IgY is the
equivalent of mammalian immunoglobulin G (IgG), although there are differences in
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structure and function (6). IgY is a low molecular weight serum antibody that contains
two heavy (H) and two light (L) chains and has a molecular mass of 180 kDa, which is
larger than IgG (159 kDa) (27, 28). The H chain of IgY possesses a variable domain
(VH), four constant domains (Cυ1-Cυ4) and lacks a hinge region. In contrast, the H chain
of IgG consists of a VH and three constant domains (Cγ1-Cγ3), where Cγ1 is separated
from Cγ2 by a hinge region (27). Also present in anseriform birds (ducks and geese) is an
alternatively spliced (120 kDa) form of IgY lacking Cυ3 and Cυ4, IgYΔFc. IgYΔFc
coexists with the full length IgY, is the structural equivalent of a F(ab’)2 fragment, and is
the predominant isoform produced during hyperimmunization (28). The use of IgY in
therapeutics has many advantages over the traditional use of IgG. One important
advantage is the genetic background and phylogenetic distance that distinguishes birds
from mammals. This allows IgY to target those antigens or epitopes that may be nonimmunogenic in mammals (9, 27). Avian antibodies will also recognize different epitopes
than mammalian antibodies, providing an antibody repertoire that is distinct from
mammalian antibodies (27, 89).
Most of the biological effector functions of immunoglobulins are associated with
the Fc region. The Fc mediated secondary functions of IgY, compared to those of IgG,
make IgY antibodies highly suitable for use as therapeutics (28). IgY lacks many of the
interactions with mammalian immune components that promote unwanted crossreactivities (9). IgY does not activate mammalian complement, and similarly does not
bind to human and bacterial Fc receptors on cell surfaces (27, 90). IgY does not interact
with mammalian IgG, nor does it bind to rheumatoid factors (27, 91, 92) or bacterial
antigens staphylococcus protein A or Streptococcus protein G (53, 89).
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Polyclonal avian IgY is currently being studied for its passive immunization
applications in both human and veterinary medicine. Unlike most of the mammalian
derived immunoglobulin therapeutics that require routine injections, there is increasing
evidence that the oral administration of IgY is an effective approach for passive
protection of both humans and animals. One of the most successful clinical applications
of IgY has been in the prevention of Pseudomonas aeruginosa (PA) infections in cystic
fibrosis (CF) patients. There are ongoing clinical trials in CF patients using a mouth rinse
that contains purified anti-PA IgY and when administered on a continuous basis has
shown to reduce and even prevent PA colonization, lessening the need for antibiotic
treatment (60-62, 93). Researchers determined that anti-PA IgY remained active in the
saliva for 8 hours and could be used for immunotherapy over a long period of time in the
absence of negative side effects (62, 94). The clinical application of IgY in humans is
also being studied in the prevention of Helicobacter pylori infections, the causative agent
of gastritis and gastric ulcers. Anti-H. pylori IgY has been shown to decrease bacterial
adhesion, growth, and urease activity in vitro and decrease H. pylori induced gastric
mucosal injury and inflammation in vivo (68). Patients suffering from H. pylori infections
were given a yogurt that contained 1% anti-urease IgY as well as Lactobacillus
acidophilus and Bifidobacterium species resulting in suppression of H. pylori infection
(69). Furthermore, studies using rotavirus immune bovine colostrum passively
administered during an outbreak in children both significantly reduced the risk for
rotavirus induced gastroenteritis associated diarrhea and the number of days children
experienced diarrhea (95, 96). Similarly, Vega et al. showed that anti-human rotavirus
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IgY passively administered to neonatal piglets as a cow milk supplement protected
piglets against human rotavirus (65).
In veterinary medicine, IgY produced against porcine enterotoxigenic Escherichia
coli (ETEC) fimbrial antigens decreased E. coli binding to porcine epithelial cells and
intestinal mucus in vitro (77, 97). These antibodies were given to piglets orally and
protected against E. coli infection in a dose-dependent manner (77). Similarly, IgY
specific for Salmonella enterica Serovar Enteritidis and Salmonella enterica Serovar
Typhimurium reduced Salmonella adhesion to epithelial cells in vitro and when chickens
were fed egg powder that contained the specific IgY there was a decrease in fecal
shedding, cecal colonization and the rate of Salmonella-contaminated eggs (74, 98, 99).
Another successful application of IgY has been in treating newborn calves with egg yolks
containing anti-bovine rotavirus (BRV) IgY to reduce BRV induced diarrhea (66).
Although there have been several studies demonstrating the efficacy of orally
administered IgY in treating gastrointestinal pathogens, the ability of IgY to cross the
intestinal barrier and enter the blood remains to be determined. Vega et al. reported that
no human rotavirus IgY was detected in the serum samples from IgY treated piglets,
however, it was not clear at what time post treatment the serum samples were obtained
(65). It is important to establish the bioavailability of IgY and the circumstances where
IgY may be bioavailable in order to increase the potential therapeutic applications of IgY.
There are several reasons to consider the possibility of seroconversion. IgY is a highly
stable molecule and has moderate resistance to some of the digestive enzymes,
specifically trypsin and chymotrypsin (35). The stability of IgY in the presence of pepsin
is highly pH dependent whereas activity remains high at a pH of 4 but decreases
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significantly at a pH of 3.5 and below (35, 100). Furthermore, IgY is temperature stable
up to 60°-70° C (100). In this study we used a murine model to evaluate the ability of
goose derived IgY to undergo seroconversion in a dose dependent manner both at neutral
pH and pH 8.0. We also determined the remaining IgY activity following incubation with
several proteolytic enzymes.
Materials and Methods
Ethics Statement
All research was conducted in compliance with the Animal Welfare Act and
adheres to principles stated in the Guide for Care and Use of Laboratory Animals (8th
ed.), National Research Council, 2011. All animal experiments were performed under the
approval of the University of North Dakota IACUC.
Purification of IgY and IgYΔFc from Goose Egg Yolk
Yolks were isolated and rinsed with water and then punctured to drain the
contents and diluted 1:10 with cold deionized water, stirred, and acidified to pH 5.0. The
diluted yolk was centrifuged at 10,000 x g for 30 minutes, and the supernatant was
filtered. IgY was further purified via column gradient chromatography (Avianax LLC, 13
March 2014, US20140073766 A1 patent application).
Mice
The common lab strain, B10.T(6R) mice (originally obtained as a gift from Chella
David, Mayo Clinic and College of Medicine, Rochester, MN) were bred in laminar flow
containment and were maintained in a clean conventional area within the Center for
Biological Research (CBR) at the University of North Dakota (UND).
Administration of Antibody
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Six to eight week old B10.T(6R) male mice were administered 0.1 mg or 1 mg
purified IgY or 0.1 mg IgG diluted in 1x PBS by oral gavage with a 20-gauge stainless
steel oral feeding needle (George Tiemann & Company, Hauppauge, New York). Each
experimental group consisted of 7-8 mice, and experiments were performed in duplicate.
Serum collection
Sera were collected into BD Microtainer serum separator tubes by retro-orbital
bleeding using Natelson blood collecting tubes (Plain, Fisherbrand) prior to the
administration of antibody and on various days post administration (as noted). Blood was
centrifuged for 10 min at 10,000 x g and stored at -80°C until assayed.
ELISA
The presence of IgY or IgG in the sera was determined using an ELISA. Briefly,
microtiter plates were coated with 100 µL of the capture antigen diluted in 1x PBS (Rb αWhole goose IgY, 2.5µg/mL for IgY detection; Donkey α-Goat Fc – unlabeled for IgG
detection) and stored at 4°C overnight. Plates were then washed 3 times with wash buffer
(1X PBS, 0.05% Tween-20 (Fisher Scientific) pH 7.4) and blocked with 400 µL per well
of blocking buffer (0.25% BSA (Fisher Scientific), 0.05% Tween-20 (Fisher
Scientific)1X PBS) and incubated at room temperature for 30 min. Plates were washed 3
times and 50 µL of each serum sample was added in triplicate and serially diluted down
the plates. IgY or IgG standards and naïve serum were prepared in blocking buffer and
added to the plates in duplicate. The plates were allowed to incubate for 30 min at 37°C.
The plates were then washed 3 times and blocked with blocking buffer for 10 min at
room temperature. Plates were washed 3 times and 50 µL of capture antibody
(biotinylated rabbit anti-goose IgY for IgY detection; biotinylated donkey α-goat IgG for
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IgG detection) was added to each well and incubated for 30 min at 37°C. Plates were then
washed 3 times and blocked with blocking buffer for 10 min at room temperature. 50 µL
of diluted streptavidin-HRP (Invitrogen) was added to each well and allowed to incubate
for 30 min at 37°C. The plates were washed 3 times and 50 µL of prepared OPD was
added to each well. After 15 min the reaction was terminated with the addition of 50µL of
1N H2SO4 and the absorbance was measured at A490 (Biotek).
Western Blot
Proteins were separated by SDS-polyacrylamide gel electrophoresis (SDSPAGE). 27 µL of each serum sample containing IgY (0.1mg IgY from 1 day post
administration, 0.1mg IgY from 2 days post administration, and 1mg IgY pH 8.0 from 3
days post administration) was diluted in 9 µL of 4x Laemmli sample buffer and loaded
into each of the three respective wells. The positive control naïve IgY was diluted in 1x
PBS and 9 µL of 4x Laemmli sample buffer and loaded in the control well. Proteins
resolved by SDS-PAGE were transferred to Immobilon-P membranes (Millipore Corp.,
Bedford, MA) using Tris-Glycine buffer. IgY was visualized using 1:10,000 dilution of
Rb anti-chicken IgY-AP (Sigma-Aldrich) and protein bands were visualized with
nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate.
The effects of proteolytic enzymes on IgY
For the examination of the effect of pepsin on IgY, pepsin was dissolved in 0.07
M sodium acetate buffer (pH 2.0 or pH 4.0) at a concentration of 5 µg/mL as previously
described [30]. The enzyme solution was immediately mixed with either 1 mg or 0.1 mg
99% purified goose IgY at a weight ratio of 1/200 pepsin to IgY. The mixture was then
incubated at 37°C at pH 2.0 or 4.0 for the appropriate incubation period (0-4 h). After
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incubation a 0.45 mL sample of the mixture was combined with 0.05 mL of 5.0% sodium
carbonate (for the pH 2.0 sample) or 0.05mL of 1.0% sodium carbonate (for the pH 4.0
sample) to inactivate the enzyme. The remaining IgY activity was measured by ELISA.
Trypsin or Chymotrypsin was dissolved at a concentration of 2.0 mg/mL in 50 mM Tris
buffer containing CaCl2, pH 8.0. The enzymes were mixed with either 1 mg IgY or 0.1
mg IgY at a ratio of one enzyme to 20 of IgY by weight and incubated at 37°C for the
appropriate time (0-8 h). Following incubation a 0.45 mL sample of each mixture was
mixed with 0.05 mL of phenylmethyl sulfonyl fluoride (PMSF) solution to inactivate the
enzymes. The remaining IgY activity was measured by ELISA.
Statistical Analysis
Two way repeated measures ANOVA and the bonferroni post hoc tests were
performed for the data sets given in figures 1-3. P values are represented in the figure
legends. All statistics were done using GraphPad PRISM Version 5.0d for Macintosh.

Results and Discussion
Bioavailability of IgY
Following the administration of 0.1 mg IgY by oral gavage, intramuscular (IM)
injection, or subcutaneous (SC) injection, the level of IgY present in the serum was
determined by ELISA at the specified time points. We detected IgY in the serum as early
as 24 h post administration for all routes, and the peak IgY titer was at 24 h post
administration by oral gavage at a concentration of 21158.16 ng/mL (Table 1).
Furthermore, it is important to note that at 24 h all administration routes induced similar
levels of IgY in the serum. IgY was present in the serum until day six for both the IM and
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SC routes and until day five for the oral gavage (Figure 1 and Table 1). Serum samples
from mice administered 0.1mg IgY orally were also analyzed by western blot on day 1
and 2 post administration (Figure 3). Western blot analysis confirms that IgY is present in
the serum post oral administration. We believe this is the first demonstration of
bioavailability of whole IgY. It is not clear if the titer of IgY demonstrated here is
sufficient for protection. Reports demonstrating the efficacy of orally administered IgY
support the potential of this antibody to be therapeutic. The presence of whole IgY in the
serum suggests that orally administered IgY may indeed by therapeutic for targets beyond
those located in the gastrointestinal tract. The orally available titers of IgY necessary for
protection would need to be determined based on the specific microorganism or disease
being treated. The level of IgY in the serum declines slightly faster in the orally
administered IgY group, compared to administration by other routes. The advantages of
the potential to administer IgY orally, most importantly eliminates the specially trained
medical personnel necessary for IM or SC injections, may outweigh this pitfall. Without
such requirements not only would the cost of administration decrease but the potential for
these therapeutics to be widely distributed would expand.
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TABLE 1 Serum IgY and IgG concentrations (ng/mL)

!

Antibody concentration and route of administration
0.1 mg IgY
Oral

1 mg IgY
IM

0.1 mg IgY
IM

1 mg IgY
SQ

0.1 mg IgY
SQ

0.01 mg IgG
Oral

0.01 mg IgG
IM

0.01 mg IgG
SQ

1

21158.16

105258.3

17325.23

152502.1

19193.46

73.23

420.93

515.68

2

2957.59

91490.04

7780.93

64601.88

7598.07

0

428.49

575.87

3

967.77

15403.16

1977.65

16978.34

2127.87

0

557.14

726.53

4

435.83

24286.17

854.23

6418.9

984.17

0

579.28

558.29

5

301.55

2616.86

447.09

3596.2

371.04

0

307.3

384.56

6

0

728.06

180.16

207.37

168.77

0

9.8

10.16

7

0

0

0

21.98

0

0

0

0

14

0

0

0

0

0

0

0

0
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Day post
administration
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Serum IgY ng/mL
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Figure 1. Bioavailability of IgY. IgY (0.1 mg) was administered by oral gavage,
intramuscular injection or subcutaneous injection in PBS pH 7.2. The concentration of
IgY present in the serum at various time points post administration was determined by
ELISA. Data is representative of two experiments, samples analyzed in triplicate, n=7-8.
Two-way repeated measures ANOVA and the bonferroni multiple comparisons tests
were performed. Column factor p value = 0.0029 (Figure 1A). Oral and SC
administration are significantly different on days 2 and 3 (P < 0.0001 and P < 0.01
respectively). Oral and IM are significantly different on days 1 and 2 (P < 0.0001). IM
and SQ are significantly different on day 1 (P < 0.0001).
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0.1mg
IgY Naive

D1

1mg pH 8
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D3

Figure 2. IgY detected in serum post administration. Serum samples from mice
administered 0.1mg IgY and 1mg pH8.0 were used to do western blot analysis. Lane one
is naïve IgY, lane two is serum collected 1 day post oral administration of 0.1mg IgY,
lane three is serum collected 2 days post oral administration of 0.1mg IgY, and lane four
is serum collected 3 days post oral administration of 1mg IgY pH 8.0.
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Bioavailability of IgG
The bioavailability of IgG was determined for three injection routes, IM, SC, and
by oral gavage. IgG was present in the serum 24 hours post administration for all routes
and was able to be detected in the serum as late as five days post SC or IM injection
(Table 1, Figure 3). IgG administered orally had a peak serum titer at one day post
administration whereas the peak serum titer for SC and IM injections were at days three
and four, respectively (Figure 1B). When comparing the oral bioavailabilty of IgG to that
of IgY on a molecular level, these data clearly demonstrate that there is a greater amount
of IgY than IgG in the serum at all-time points post administration. The importance of
this demonstration is that therapeutic IgY may uniquely be given orally, whereas there
are currently no approved IgG treatments that are administered orally, likely due to the
very low bioavailability.
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Figure 3. Bioavailability of IgG. IgG was administered by oral gavage, intramuscular
injection, or subcutaneous injection in PBS pH 7.2. The concentration of IgG present in
the serum at various time points post administration was determined by ELISA. Data is
representative of two experiments, samples analyzed in triplicate, n=7-8. Two-way
repeated measures ANOVA and the bonferroni multiple comparisons tests were
performed. Column factor p value = 0.0006 (Figure 1B). IgG SC and IgG oral are
significantly different on days 1-5 (P < 0.001). IgG IM and IgG oral are significantly
different on days 1-5 (P < 0.001). IgG IM and IgG SC are different on day 2 (P < 0.05).

!

37!

!

Bioavailability of orally administered IgY (1 mg) after multiple doses
To determine if the titer of bioavailable IgY could be increased by increasing the
dose or 1 mg of IgY was administered by oral gavage either once, or three times as part
of a multiple dose schedule at 0 h, 12 h, and 24 h. With multiple administrations, IgY was
detected in the serum as early as 24 h after the final antibody dose (48 h after the first
dose). However, when a higher concentration (1 mg) of IgY was administered as a single
dose, IgY was undetectable the serum at any time point post administration (Figure 4).
This was surprising, as the previous experiments using orally administered IgY at a lower
dose demonstrated the presence of IgY in the sera. We expected that IgY administered at
a higher dose (1 mg) would also be bioavailable. The mechanism by which IgY
seroconversion occurs only at a lower dose during single administration is unknown and
is currently being investigated. Overall, these data suggest that depending on the
concentration of IgY administered, it would be advantageous to design a therapeutic
strategy that would include a multiple dosing schedule. When IgY was administered at a
higher concentration (1mg) dose the bioavailability followed a similar trend in the IM
and SC groups but not in the orally administered group (Table 1).
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Figure 4. Bioavailability of IgY increases with multiple doses. IgY was administered by
oral gavage in PBS pH 7.2 either once or at multiple time points (0 h, 12 h, 24 h). The
concentration of IgY present in the serum at various time points post administration was
determined by ELISA. Data is representative of two experiments, samples analyzed in
triplicate, n=7-8. Two-way repeated measures ANOVA and the bonferroni multiple
comparisons tests were performed. Column factor p value = 0.0008. On days 2 and 3 P <
0.0001.
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Bioavailability of IgY in PBS pH 8.0
To further investigate why IgY was not able to seroconvert at a higher dose we
looked into ways to alter the antibody conditions without changing the dose. In this
experiment IgY was administered by oral gavage in PBS at either pH 7.2 or pH 8.0 and
the level of IgY present in the serum was determined at the specified time points. When
IgY was administered in PBS buffered to pH 8.0, the orally administered IgY was
detected in the serum at 48 h post administration at a level of 45,760 ng/mL.
Seroconversion still did not occur when IgY was administered as a single dose in a pH
7.2 solution, as demonstrated above (Figure 5). We were able to demonstrate that by
increasing the pH of the solution the higher concentration of IgY became bioavailable.
These data suggest that increasing the pH of the antibody solution is better than both the
low dose and the multiple dose strategy. The level at 24 hours is over double that of the
0.1mg IgY administration and approximately sixty times higher than the oral
administration of IgG. Furthermore, when the pH is increased the IgY remains at a higher
level in the serum over time. At day five, 1mg IgY in pH 8.0 is at an average of 3807
ng/mL whereas at day five 0.1mg IgY is at an average of 301.5 ng/mL and IgG is absent
by day five. Further investigation is ongoing to elucidate a mechanism as to why
increasing the pH proves to be advantageous, however one possible explanation is that
the increased pH solution is able to buffer the acidic environment of the stomach. If the
stomach acid is in some way changing the behavior or structure of the IgY in a way that
prevents it from being passed into the small intestine and absorbed, then by adding a
buffer to counteract the acid may offer some protection to these antibodies allowing them
to seroconvert. Furthermore, these data do suggest that other potential formulations and
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manipulations of IgY may be beneficial in order to be used orally. One alternative would
be to microencapsulate the IgY, which may aid in both protecting IgY from proteolytic
enzymes in the gastrointestinal tract and increasing the bioavailability.
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Figure 5. Bioavailability of IgY increases in PBS pH 8.0. IgY was administered by oral
gavage in PBS pH 7.2 or PBS pH 8.0. The concentration of IgY present in the serum at
various time points post administration was determined by ELISA. Data represented
follows the same trend in both experiments, samples analyzed in triplicate, n=7-8. Twoway repeated measures ANOVA and the bonferroni multiple comparisons tests were
performed. Column factor p value < 0.0001. On days 2 and 3 P < 0.0001, on day 5 P <
0.01.
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Behavior of IgY against proteolytic enzymes
Previously it has been shown that chick IgY is more resistant to specific
proteolytic enzymes, compared to mammalian IgG. Therefore we want to determine if
goose-derived IgY also demonstrated this resistance, and to determine if the resistance
was concentration-dependent, in light of the ability of buffering the high dose orally
administrated IgY to obtain bioavailability. In these experiments we determined the
amount of IgY activity remaining following the incubation of either 0.1 mg or 1 mg IgY
in pepsin (pH 2.0), pepsin (pH 4.0), trypsin, or chymotrypsin. We detected no dosedependent difference in the proteolytic resistance, regardless of the IgY dose. IgY
incubated with pepsin (pH 4.0) retained more activity than IgY incubated with pepsin
(pH 2.0). Incubation of IgY with trypsin or chymotrypsin had much less effect on the
degradation of IgY, with 50-70% of the antibody activity still remaining after 8 hours of
incubation. The degradation of IgY incubated in PBS alone was measured as a control,
and 100% activity remained after 8 hours (Table 2). These results are in agreement with
previous studies (39), and suggest that when administered orally IgY is able to withstand
partial activity, which is highly advantageous over the use of IgG that tends to be less
stable. Unfortunately these data did not explain the difference we see in the
bioavailability between the high and low doses of IgY.
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TABLE 2 Behavior of IgY against proteolytic enzymes
1 mg IgY Pepsin pH 2.0

0.1 mg IgY Pepsin pH 4.0

1 mg IgY Pepsin pH 4.0

Titer

%Recovery

Titer

%Recovery

Titer

%Recovery

Titer

%Recovery

0 hours

97272.23

100

1180302.43

100

97272.23

100

1180302.43

100

1 hour

29137.86

29.9

387101.53

32.7

38518.23

39.5

557631.03

47.2

2 hours

27091.4

27.8

295364.4

25.0

41580.6789

42.7

388228.96

32.8

4 hours

22102.74

22.7

297198.6

25.1

41944.74

43.1

389606.12

33.0

Incubation
period

!

0.1 mg IgY Pepsin pH 2.0

0.1mg IgY Trypsin

1mg IgY Trypsin

0.1mg IgY Chymotrypsin

1mg IgY Chymotrypsin

Titer

%Recovery

Titer

%Recovery

Titer

%Recovery

Titer

%Recovery

0 hours

97272.23

100

1180302.43

100

97272.23

100

1180302.4

100

1 hour

82685.38

85.0

873275.47

73.9

79241.61

81.4

928249.76

78.6

2 hours

77365.61

79.5

817156.15

69.2

56926.25

58.5

752834.10

63.7

4 hours

64414.82

66.2

703863.25

59.6

75315.67

77.4

673075.81

57.0
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CHAPTER III
IGY TREATMENT FOR MURINE CEREBRAL MALARIA
Abstract
Increasing evidence for drug resistant Plasmodium strains suggests there is a
substantial need for new or additional therapeutic options. Cerebral malaria (CM), a
manifestation of severe Plasmodium falciparum infection is a clinical disease that can
lead to lasting neurological and cognitive disorders and is yet to be cured. Although the
pathogenesis of CM is not well characterized, the use of Plasmodium berghei ANKA has
been accepted as a commonly used model organism to study CM in mice. Here we used
this murine model of CM to evaluate the efficacy of a combination of two anti-malaria
IgY antibodies: anti-Plasmodium IgY and anti-MSP-1 IgY.
C57BL/6 male mice were infected intraperitoneally with 1.0 x 107 Plasmodium
berghei ANKA infected red blood cells (iRBC). Mice were treated subcutaneously on
days 2 and 4 or days 2 and 5 post infection with a combination of anti-Plasmodium IgY
and anti-MSP-1 IgY, naïve IgY, or PBS. Survival and clinical signs of CM were
monitored daily and thin blood smears were collected and Giemsa stained to determine
parasitemia daily as well.
Mice that were treated with a combination of anti-Plasmodium and anti-MSP-1
had significantly increased survival rates as compared to both the naïve IgY treated and
PBS treated control mice. Parasitemia was also reduced in the malaria antigen IgY treated
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mice and this decrease corresponded to the timing of treatment. IgY therapy delayed
mortality in the murine model of CM.
Goose-derived anti-Plasmodium and anti-MSP-1 IgY is able significantly extend
the times to death in mice infected with Plasmodium berghei ANKA. These data provide
evidence for anti-malaria IgY as a potential candidate to be used in antimalarial
combination therapy.
Introduction
The decreasing efficacy of the currently approved anti-malarial drugs for the
treatment of severe malaria facilitates the need for new drugs and/or the exploitation of
different drug classes. Most of the drugs that have been approved for treatment of malaria
patients are artemisinin derivatives (101). Artemisinin derived anti-malarial drugs are
highly important because of their efficacy against multidrug-resistant strains of
Plasmodium falciparum (P. falciparum). One disadvantage of artemisinin drugs is the
occurrence of recrudescence when given in short course monotherapy (102). Therefore,
artemisinin derivatives are often used in combination with other antimalarial drugs to
provide both rapid and long-lasting protection. Artemisinin was isolated in 1972 by a
group of Chinese researchers from the Artemisia annua plant. Artemisinin derivatives
work at the early trophozoite and ring stages of parasite development, unlike other drugs
that work only during the later stages (trophozoite and schizont). Therefore, artemisinin
has been successful in treating patients suffering from uncomplicated malaria, but
unfortunately its efficacy is reduced in complicated cases of malaria, such as cerebral
malaria (CM). Even after intramuscular treatment with artemether, an artemisinin
derivative, the mortality rate of children with CM is 15-25% (102). Furthermore,
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researchers have identified human-infecting Plasmodium strains that are resistant to
artemisinin drugs (103). The mechanism of drug resistance in such parasites is an area of
active research and debate (104).
Malaria is a global disease that affects millions of people every year.
Approximately 3.4 billion people within 106 countries and territories live in areas that are
at risk for malaria transmission, and in 2012 the World Health Organization estimates
that malaria caused over 207 million clinical episodes and approximately 627,000 deaths
(105). The life cycle of the parasite involves both hepatic and erythrocytic stages and the
clinical manifestations of disease occur following erythrocyte rupture (106). There are
five species of Plasmodium that are infectious to humans, however P. falciparum is the
parasite responsible for the development of severe malaria (107).
CM is a clinical syndrome, a neurological complication, which is the result of a
severe infection of the parasite P. falciparum. CM is characterized by the presence of
parasites in the blood, and as a diffuse encephalopathy resulting in an altered level of
consciousness (e.g. coma) in the absence of other causes of encephalopathy (108). CM is
the leading cause of hospitalization and mortality of children under the age of five in subSaharan Africa and accounts for approximately 80% of all fatal cases of malaria (109,
110). In the absence of treatment, CM is nearly universally lethal and, even with
intervention, the mortality is still 15-20% (111). Following treatment for CM, patients
often exhibit permanent residual symptoms, including cognitive, behavioral, and motor
changes (112).
There are two leading theories describing the pathogenesis of CM: the first is the
obstruction of cerebral microvasculature by sequestered Plasmodium-infected red blood
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cells (iRBC); and the second is an immunopathology caused by the exacerbation of the
host inflammatory response (113). The assessment of CM pathogenesis in humans is
especially difficult due to the invasiveness required to accurately assess human brain
tissue. Experimental cerebral malaria (ECM) is currently modeled in mice using
Plasmodium berghei ANKA (PbA) infection. ECM has been valuable providing a wealth
of information about the pathogenesis of CM despite the functional differences in
Plasmodium pathogenesis between humans and mice (114). In the ECM model the
neurological syndrome is associated with severe vasculopathy and a systemic
inflammatory response. There are several factors that contribute to this disease state
including the activation of leukocytes, cytokine production, and increased expression of
endothelial adhesion molecules (115).
Merozoite surface protein 1 (MSP-1) is the most abundant protein on the surface
of P. falciparum merozoites, which are the invasive form of the parasite (116). MSP-142
(42 kDa) is synthesized initially as a large precursor during intracellular merozoite
development and then is expressed as a GPI-linked protein in complex with MSP-6 and
MSP-7 on the surface of a replicating merozoite inside of the iRBC (116). Between
merozoite release and the completion of erythrocyte invasion, MSP-142 undergoes
proteolytic processing that results in the formation of two MSP fragments, MSP-133 and
MSP-119. The majority of the MSP-1 complex, the MSP-133 fragment, is then shed from
the parasite surface leaving only the C-terminal MSP-119 fragment intact. Antibodies that
are specific for MSP-119 were able to block merozoite invasion of RBCs and the
development inside the iRBC in an in vitro assay (117). Other reports have described the
potential of anti-MSP antibodies in malaria vaccines (118-120). There is also evidence
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that MSP-1 is essential for parasite survival as efforts to disrupt or knock out the msp1
gene have been unsuccessful (121).
In this study we tested the ability of goose derived anti-MSP-1 and antiPlasmodium IgY antibodies to treat ECM. IgY is the predominant antibody isotype found
in birds and is located in both the serum and egg yolk. Also present in anseriform birds
(waterfowl, e.g.ducks and geese) is an alternatively spliced IgY isoform called IgYΔFc
that lacks two constant domains present in full length IgY and is the functional equivalent
of an IgG F(ab’)2 fragment. The IgYΔFc isoform is also the most prevalent antibody
produced following hyperimmunization (28). Although IgY and IgG are functionally
similar molecules, there are several characteristics of IgY that make it an attractive
alternative to using conventional mammalian antibodies for the treatment of infectious
agents in mammals. The genetic background and phylogenetic distance between birds
and mammals is critical difference between these two antibody sources that allows avian
IgY to recognize epitopes that may not be recognized by mammals. IgY does not bind to
mammalian complement to induce an inflammatory reaction (48). IgY does not bind to
human rheumatoid factor, and has decreased binding to bacterial proteins Staphylococcus
protein A or Streptococcus protein G (51-54, 92). The binding of IgY to Fc receptors is
also drastically reduced when compared to the binding of Fc receptors by IgG (90). There
have been several reports of experimental and clinical trials indicating the efficacy of IgY
for the treatment of infectious diseases (27, 39, 61, 64, 68, 71, 75, 79, 93, 98, 100, 122124). We demonstrate here that anti-Plasmodium IgY in combination with anti-MSP-1
IgY is able to increase the time to death and decrease the parasitemia in PbA infected
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mice. These data suggest that IgY is a putative therapeutic that could be used in new
combination therapy for malaria.

Materials and Methods
Ethics statement
All research was conducted in compliance with the Animal Welfare Act and
adheres to principles stated in the Guide for Care and Use of Laboratory Animals (8th
ed.), National Research Council, 2011. All animal experiments were performed under the
approval of the University of North Dakota IACUC committee.
Plasmodium berghei ANKA
Plasmodium berghei ANKA (PbA) was obtained from BEI resources and
maintained by successive infection of C57BL/6 male mice. On day 6 p.i. blood was
collected by retro orbital bleeding with a Natelson blood collecting tube (Fisherbrand)
and placed into a BD vacutainer with sodium heparin to prevent clotting. Experimental
mice were inoculated intra-peritoneally with 1.0 x 107 iRBC in 100µL of PBS. Blood
smears were collected daily starting at day 3 post infection and stained to analyze
parasitemia.

Mice
Mice were bred in our breeding colony and maintained within a clean
conventional area in the Center for Biological Research at the University of North
Dakota. C57BL/6 male mice between the ages of 6-8 weeks were used for the infection
studies. All mice were assessed for survival and signs of CM were monitored daily.
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Generation of blood Smears for determining parasitemia
Blood was collected from all experimental mice via tail clip and a drop of blood
was placed on a clean slide (Fisherbrand). A second slide was used to create a thin smear.
Slides were then fixed with methanol and allowed to dry for 30 minutes. Each slide was
stained in a dilute solution of Giemsa stain (Sigma-Aldrich) for 1 hour and allowed to air
dry. Slides were viewed using a 100x oil immersion lens.
Parasitemia was determined by counting the number of iRBC/500 RBC in Giemsa
stained blood smears. Parasitemia was calculated for each experimental mouse and the
daily average parasitemia was calculated for each group.
Anti-Plasmodium IgY
Geese, three for each antigen, were vaccinated subcutaneously with killed whole
Plasmodium berghei parasite previously isolated from iRBCs or the MSP-1 antigen
(yeast secreted recombinant 19 kDa carboxy-terminius of MSP-1 from Plasmodium yoelii
lethal strain (XL), ATCC) at day 0, followed by booster injections on weeks 2, 4, and 6.
Geese were then bled between 6-8 weeks and serum was obtained using a 10,000 x g, 30
minute spin at 20°C. The serum was filtered through a PES 0.22 µm filter unit and a
series of precipitation steps were carried out to obtain the antibody populations.
Following this, MEP HyperCel Chromatography was performed using a 30 mL MEP
HyperCel (Pall Biosciences) column at 5 mL/minute. The column was washed and IgY
was eluted using a 50 mM acetate buffer step gradient. Antibody fractions were
combined and placed into a 500 mL chamber of Water’s LabScale Tangental Flow
Filtration (TFF) apparatus with a Pellicon XL TFF PES membrane (100,000 MW
cutoffs). Samples were concentrated and diafiltration was performed with 1x PBS.
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Antibody treatment
Experimental mice received a combination of anti-Plasmodium or anti-MSP-11
antibody on either on days 2 and 5 post infection (p.i.), or on days 2 and 4 p.i.
subcutaneously, as outlined. Each antibody type was injected separately into a different
site on the mouse as to avoid potential unwanted interference. Specifically mice were
injected into the loose skin above the neck, and into the loose skin further down the back
near the dorsal rump. Multiple injections were performed within 15-20 minutes of each
other to prevent any leakage from the initial injection site.
Statistical analysis
Survival curves were analyzed using the log-rank (Mantel-Cox) test and p values
are reported in the text and figure legends. All statistics and figures were made using
GraphPad PRISM version 5.0d for Macintosh.
Results
IgY therapy of CM
Treatment on days 2 and 5 p.i.
C57BL/6 mice infected with PbA were administered anti-MSP-1 IgY, antiPlasmodium IgY, a combination of both antibodies, or PBS via a subcutaneous route of
infection on days 2 and 5 p.i.. Parasitemia was calculated from daily blood smears. Mice
that received the combination of the two antibodies showed the greatest initial survival,
although all treatment groups had similar survival rates at 21 days p.i. with approximately
30% survival (Figure 6). All mice, regardless of treatment, did eventually succumb by 23
days post infection. There was no statistically significant difference between any of the
treatment groups. However, these data suggested that the anti-Plasmodium and anti-MSP!
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1 IgY antibodies offered protection that allowed these mice to survive longer than the
PBS control treated mice.
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Figure 1
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Figure 6. Prolonged day to death following IgY treatment on days 2 and 5 p.i. C57BL/6
male mice ages 6-8 weeks were infected by intraperitoneal route with 1.0 x 107 infected
red blood cells previously harvested from an infected mouse. Cells were injected in a 1x
PBS vehicle solution. On days 2 and 5 post infection a groups of mice (n=7-8/group)
were administered anti-Plasmodium IgY (anti-Parasite), anti-MSP-1 IgY, a combination
of both antibodies (combination) or PBS via subcutaneous route. Survival was monitored
daily.
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Treatment on days 2 and 4 p.i.
We observed, as others have reported (125) that death associated with PbA
infection typically started within 7 days post infection. Therefore, in order to examine the
kinetics of treatment and provide potentially better protection with the anti-Plasmodium
and anti-MSP-1 antibodies, the administration schedule was altered to days 2 and 4 p.i.
with PbA. Mice treated with the combination of anti-Plasmodium and anti-MSP-1
antibodies survived significantly longer, day 21 p.i. compared to day 7 with PBS
treatment and day 10 with the naïve IgY antibody treatment, p = 0.0007 and p= 0.045
respectively (Figure 7). This demonstrated that malaria-specific IgY was able to
significantly prolong the day to death in mice infected with PbA.
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Figure 2
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Figure 7. Prolonged day to death following IgY treatment on days 2 and 4 p.i. C57BL/6
male mice ages 6-8 weeks were infected i.p. with 1.0 x 107 infected red blood cells
previously harvested from an infected mouse. Cells were injected in a 1x PBS vehicle
solution. On days 2 and 4 post infection groups of mice (n=7-8/group) were administered
anti-Plasmodium IgY and anti-MSP-1 IgY (combo Ab), naïve IgY, or PBS via
subcutaneous route. Survival was monitored daily. A log rank (Mantel-Cox) test was
performed between the PBS control group and the combination IgY treatment group p
value = 0.0007. A log rank (Mantel-Cox) test was performed between the naïve IgY and
combination IgY treatment p value = 0.045.
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To better understand the protection provided by the anti-Plasmodium and antiMSP-1 IgY antibodies, parasitemia by Giemsa-stained thin film blood smears was
determined. Parasitemia was calculated daily starting on day 3 post infection as shown in
Figure 8. Parasitemia was lower in the antibody treated group by day 4 p.i., rapidly post
treatment on day 2. Both the PBS control and naïve IgY control groups had higher
parasitemia on all days following treatment with the greatest notable difference at day 8
post infection. Between days 12 and 13 the parasitemia started to rise again in the
malaria-antigen specific IgY treated groups until the day of death (Figure 8).
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Figure 3
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Figure 8. Decreased parasitemia in mice treated with IgY on days 2 and 4 p.i. C57BL/6
male mice ages 6-8 weeks were infected by intra peritoneal route with 1.0 x 107 infected
red blood cells previously harvested from an infected mouse. Cells were injected in a 1x
PBS vehicle solution. On days 2 and 4 post infection groups of mice (n=7-8/group) were
administered anti-Plasmodium IgY and anti-MSP-1 IgY (combo Ab), naïve IgY, or PBS
via subcutaneous route. Thin blood smears were made from the blood of each mouse
starting at day 3 post infection. Each slide was fixed and stained with dilute Giemsa stain.
Parasitemia was calculated by counting the number of infected red blood cells per 500
red blood cells for each mouse.
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Discussion
The current situation regarding the parasitic resistance to artemisinin derivatives
in malaria patients has pushed the World Health Organization to recommend artemisinin
based combination treatments instead of a monotherapy approach to treating malaria
infections. There have been several studies determining the efficacy of different
artemisinin derivatives in combination with other anti-malaria compounds (126).
Unfortunately there are indications of resistance to drugs that may be used in artemisinin
based combination therapies, e.g. Malarone ® which is a combination of atovaquone and
proguanil (127). Artemisinin treatments, despite many interventions, have not been able
to cure severe complicated malaria and overall there has been no significant difference in
the neurological sequelae with this treatment (102). These data highlight the need for new
anti-malaria compounds or immunotherapies that could be used as part of an artemisinin
based or other combination therapy. In this study we demonstrate that PbA infected mice
that are treated with a therapeutic antibody on either days 2 and 4 or on days 2 and 5 p.i.
succumb to the infection at a slower rate than those without treatment. We also show that
mice that receive IgY treatment have decreased parasitemia that correlates with when the
antibodies were administered and the time of death. The administration of malaria
antigen-specific IgY at a later time point did change the statistical significance of the data
although the trends remained similar (data not shown). It has been previously
demonstrated that polyclonal antibodies can prevent erythrocyte invasion by merozoites
in vitro (128, 129). It has also been demonstrated in several studies that IgY is safe for
human consumption and has less unwanted reactivities with host proteins than does other
mammalian antibody treatments. We understand that IgY is not a candidate for
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monotherapy treatment of malaria, however we do propose that anti-Plasmodium IgY and
anti-MSP-1 IgY would be a good alternative cocktail for use in combination therapies.
Further studies are necessary to determine what antibody-drug combinations and
treatment regimes provide the best protection, and if antibody therapy is able to prevent
neurological damage to a greater extent than other drugs used in combination therapy for
severe cerebral malaria.
Conclusions
In summary, the data presented in this study offer evidence that a combination
treatment with other potential drug candidates and anti-Plasmodium and anti-MSP-1 IgY
may offer increased protection. Here we demonstrate that IgY treatment delayed the time
between infection and death and has decreased the parasitic load in these infected
animals. Elaboration on this preliminary study will include the investigation of the
efficacy of IgY in combination with other antimalarial drugs.
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CHAPTER IV
PASSIVE IMMUNIZATION OF IGY FOR THE TREATMENT OF DENGUE
VIRUS INFECTIONS
Abstract
Dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) are severe
disease manifestations following secondary heterotypic dengue virus (DENV) infections.
At present, there are no licensed therapies or vaccines to treat DENV induced disease.
DHF and DSS are mediated by serotype cross-reactive antibodies that facilitate antibody
dependent enhancement (ADE) by binding to viral antigens and then Fcγ receptors
(FcγR) on additional myeloid cells. Balsitis et al. have verified using genetically
engineered DENV specific antibodies that the interaction between the Fc portion of the
serotype cross-reactive antibodies and the FcγR is required to induce ADE (130).
Additionally, they demonstrated that these antibodies were as neutralizing as their nonmodified variants, were incapable of inducing ADE, and were therapeutic following a
lethal, antibody-enhanced infection. We therefore hypothesized that avian IgY that do not
interact with mammalian FcγR, would provide a novel therapy for DENV induced
disease. In this study, polyvalent anti-DENV2 IgY were purified from the eggs of
DENV2-immunized geese. The neutralization and enhancement capacity of anti-DENV2
IgY was tested in vitro, and the therapeutic efficacy against lethal challenge was tested in
vivo. It was determined that anti-DENV2 IgY neutralized DENV2 and did not induce
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ADE in vitro. Anti-DENV2 IgY was also protective in vivo when administered 24 hours
following a lethal DENV2 infection. The anti-DENV2 IgY were separated into the “full
length” and “alternatively spliced (Δ)” antibody populations and DENV2-specific
epitopes were mapped and compared to the well-characterized DENV and flavivirus
epitopes. Anti-DENV2 IgY recognized some but not all well characterized DENV
epitopes, the two antibody populations recognized different epitopes, and both
populations recognized uncharacterized epitopes. Peptide selection of the anti-DENV2
antibodies based on the unique DENV2 epitopes was completed to test the neutralization
capacity in vitro. These findings support the potential of avian antibodies as a new
treatment for DENV infection.
Introduction
Dengue virus epidemiology
Almost half of the world is at risk for dengue virus infections with up to 390
million possible infections occurring in nearly 100 endemic countries annually (131).
Dengue is a fast emerging disease with a 30-fold increase in disease incidence reported in
the past 50 years (132). Dengue has established itself globally in both endemic and
epidemic transmission cycles and is currently regarded as the most important arboviral
disease internationally (91, 131, 133).
DENV is a member of the Flavivirus family of RNA viruses. There are four
distinct serotypes (DENV1, DENV2, DENV3, DENV4) that differ at the amino acid
level by 25-40% (134). It has been estimated based on genetic studies of the four
different serotypes that these serotypes emerged from a common ancestor virus that
circulated between non-human primates and mosquitoes some 500 years ago. Following
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this it is likely that each virus serotype emerged separately into a human urban
transmission cycle (135). DENV is primarily transmitted by the Aedes aegyptii mosquito
and Aedes albopictus is a secondary vector. Mosquitos transmit DENV to humans by
feeding on previously infected human hosts. Following the incubation period in the
mosquito, the mosquito is infectious and can release the virus upon feeding on another
human host (136, 137).
It has been suggested that the principle mosquito vector Aedes aegyptii originated
in Africa and that the exportation of DENV to the Western Hemisphere occurred
approximately 400 years ago. The exportation likely occurred in multiple introductions in
association with the slave trade (138). The first recognized dengue outbreaks occurred
early in the 17th century with the firsts reported on the Caribbean islands of Martinique
and Guadeloupe. During these outbreaks patients reported symptoms including fever,
severe headache, lassitude, and pains in the legs. During a 1780 outbreak in Philadelphia
Benjamin Rush coined the term “break-bone fever” (91). In the early years DENV was
considered a nuisance disease with very low mortality rates. The earliest known cases of
possible DHF/DSS were in India during the 1870s as the 4 different serotypes began to
spread globally and reinfection became common (139). During the early 20th century the
mosquito vector began to spread and DENV became prevalent in more tropical areas of
the globe. There have been several suggested factors that explain the expansion of the
mosquito vector including the international travel and urbanization and globalization
following World War II and an increase in standing water as a result of poor housing
situations, water systems, and improper sewer and waste management systems (133).
During the 1950s the first documented epidemics of DHF occurred, first in the
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Philippines (1953-1954) and Thailand (1958) (133). In the Americas, epidemic dengue
was controlled in most of the region by the eradication program that eliminated the Aedes
aegypti mosquito vector from 23 countries until the program was terminated in the early
1970s (140). Following this the mosquito vector was rapidly reestablished and new
DENV serotypes and strains emerged, causing the co-circulation of multiple DENV
serotypes (133).
In 1980 DENV1 was isolated from a 5-year-old girl in Brownsville, Texas,
representing the first indigenous case of dengue since the initial case in 1945. (141).
Since then there have been further reported cases of dengue in Brownsville, TX and in
Florida and the presence of DENV1 has been detected in Aedes aegypti mosquitos in
Florida (141, 142).
It is important to realize that the spread of the virus is ultimately dependent on the
mosquito vector and thus vector control is crucial. Unfortunately, to effectively control
the mosquitoes that live in close contact with the human host, every house and office in
the city must be visited on a daily basis and this has proven to be nearly impossible
without effective community outreach programs (133). It has become clear that in order
to control the disease in the absence of a strong vector control program there needs to be
the development of new antiviral therapies and vaccines.
DENV characteristics and replication
DENV is an enveloped positive-strand RNA virus. The mature DENV contains
three structural proteins, the capsid protein (C), membrane protein (M), and the envelope
protein (E); and seven nonstructural proteins, NS1, NS2A, NS2B, NS3, NS4A, NS4B,
NS5 (143). The structure of the virus includes a viral nucleocapsid surrounding the RNA
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genome composed of multiple copies of the C protein. Surrounding the nucleocapsid is a
host-cell-derived lipid bilayer, in which 180 copies of the M and E proteins are anchored.
The M protein is proteolytic fragment of the precursor protein Pre-membrane (PrM).
DENV naturally infects cells of the mononuclear phagocyte lineage (e.g.
monocytes, macrophages, and dendritic cells) as well as the skin-resident Langerhans
cells (144, 145). It is unknown what receptor(s) DENV attaches to the on the cell surface
to facilitate entry but it has been suggested that possible receptors are DC-SIGN, and the
closely related L-SIGN (146, 147). In addition to these two receptors it was recently
demonstrated that the carbohydrate moieties on the DENV E protein can bind to the
mannose receptor expressed on human macrophages (148). DENV use clathrin-mediated
endocytosis to enter the host cell and upon internalization they are delivered to Rab5positive early endosomes. Once the endosome as matured into a Rab7-positive late
endosome the virus and host cell membrane fusion occurs (149). Following this the viral
nucleocapsid is released into the cytoplasm. As the replication machinery of positive
strand RNA viruses is not packaged in the viral particle, the DENV must undergo an
initial round of translation, to generate viral replicase, upon entry into the cell. The
DENV genome is translated as a single polyprotein and is later co-and posttranslationally cleaved into respective proteins. During this initial translation the
structural proteins are anchored in the endoplasmic reticulum (ER). Following the
proteolytic cleavage of proteins, dengue virions are assembled on the membrane of the
ER. The C protein remains associated with the ER and the PrM and E proteins form
heterodimers on the luminal side (150).
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After the initial translation episode the virus begins to replicate inside the host cell
cytosol. Several nonstructural proteins are required for successful replication of the
dengue RNA. Negative strand synthesis begins upon assembly of NS5 with the other
components of the DENV replicase, NS3, NS1, NS2A, NS4A and NS4B. Negative strand
synthesis results in the formation of a double stranded replicative form. The replicative
form undergoes transition into a replicative intermediate, and this is a process that likely
involves genome cyclicization. Viral replication proceeds on this replicative intermediate
asymmetrically and semi-conservatively resulting in the predominant production of
positive strand RNA. Once the newly synthesized RNA is present the C protein forms a
nucleocapsid around the RNA genome. Immature virions are formed after heterodimers
of PrM and E are oriented into the lumen, as previously stated. The immature virion
travels through the trans-golgi network where the acidic environment causes dissociation
of the PrM and E proteins. Dissociation allows the PrM proteins to be cleaved by furin
protease to form a mature virion. As the new virus exits the golgi it fuses with the host
cell membrane and is released by exocytosis (151, 152).
DENV pathogenesis
DENV can affect people of all ages including infants, children, adults and elderly
but the interplay between the virus and host is what determines the clinical outcome.
Disease manifestations from DENV infections range from asymptomatic infections, a
mild febrile illness known as dengue fever (DF), or the more severe DHF and DSS.
During an initial infection, most children experience subclinical infection or mild
undifferentiated febrile syndromes (153). In this situation, lifelong immunity against the
primary infecting virus occurs. During a secondary infection the pathophysiology of the
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disease changes dramatically, specifically if the secondary infection is with a different
DENV serotype. Heterotypic secondary infections are the cause of 90% of the DHF cases
reported (154). One working hypothesis of dengue pathogenesis during severe disease is
the result of ADE during secondary infections (153).
ADE occurs when remaining sub-neutralizing antibodies following a primary
DENV infection bind to an infecting viral particle from the secondary heterotypic
infection. These antibody-virus complexes then bind to Fc receptors on macrophages and
dendritic cells via the FcγR of the antibody (143). The result of ADE is a higher number
of infected cells and therefore a heightened immune response to the infection (143). ADE
also results when infants are born to dengue immune mothers (155). In this situation
antibodies transferred from the mother to the child for the first 4 months postpartum
protect children, but after this the antibodies become non-neutralizing and the child
becomes at risk for ADE. When the child reaches one year the anti-DENV antibody
levels decline and the child is no longer at risk for severe disease (156, 157).
During an initial infection with dengue patients often have no symptoms or they
present symptoms such as fever, malaise, headache, body pains, and rash that are
characteristic of DF. At this point, clinicians cannot predict if these patients will progress
to severe disease!(153, 158). However, most of these patients will go on to recover from
the disease within a week to ten days of onset (159). Viremia is apparent 1-2 days prior to
the onset of symptoms and peaks during the first 2 days of fever. About 5% of the
patients that report with symptoms of DF will go on to have DHF or DSS. The critical
period in DHF starts at the moment of defervesence but it is possible that haemorrhagic
manifestations may occur 24 hours earlier. DHF is characterized by a high fever,
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haemorrhagic manifestations, thrombocytopenia (platelet count 100,000/mm3 or less),
haemoconcentration (> 20% difference), and 10 to 100 fold higher viremia than in DF.
Petechiae, epistaxis, bleeding at the venipuncture sites, gum bleeding, and haematemesis
are also observed in some patients. The most significant pathophysiological even that
characterizes severe disease is plasma leakage. Signs of circulatory failure are also
apparent in patients with severe disease (irritability, cold extremities, restlessness, flushed
face). At this point it is important to closely monitor these people for signs of progression
to shock such as intense abdominal pain, persistent vomiting, a weak pulse, and
hypotension (160). DSS results during the onset of increased vascular permeability and is
characterized by the leakage of plasma fluids into the interstitial spaces inducing
hypovolemic shock (161). Once a patient is in shock due to DENV infection it is likely
that they will either survive or succumb to infection within 24 hours (162).
Treatment of DENV induced disease currently involves treating the symptoms,
specifically rehydration therapy and the use of pain relievers such as acetaminophen.
There have been several attempts to make antiviral therapies and vaccines. One problem
that has been encountered is the need for a therapy that will protect against all four strains
of DENV. Another challenge is the need for treatment early in the course of illness, often
before patients have a confirmed dengue infection. At present there remains an unmet
need for an effective dengue therapeutic that is able to shorten the duration of the illness,
prevent the development into severe disease, and reduce the severity of common
symptoms (163). There are a number of institutions, both academic and pharmaceutical,
that are currently engaged in the discovery and development of DENV therapeutics
(163). One encouraging area of research has been the development of therapeutic anti!
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DENV monoclonal antibodies that block viral infection. Although it is unlikely that a
single monoclonal antibody will be able to neutralize all four DENV serotypes, a potent
neutralizing antibody cocktail is a likely candidate (130, 163). It should be remembered,
however, in addition to effective therapeutic intervention we need to focus on an
integrated approach that also aims to control the mosquito vector, especially in the case
of Aedes aegypti that transmits several diseases (133).
Immune response to DENV
The first line of defense against DENV infection is the recognition of the virus by
host cell molecules, specifically pattern recognition receptors such as toll-like receptors
(TLRs). The TLRs that are primarily involved in dengue viral recognition are TLR-7 and
TLR-3, which recognize DENV RNA after endosomal acidification (164). Recognition of
viral RNA by TLR-3 results in a series of phosphorylation events that leads to the nuclear
translocation of interferon regulatory factor 3 (IRF3), activator protein 1 (AP-1), and NFκB. This induces the production of IFN-α/β, interferon stimulating genes, and
chemokines (165). In addition to TLR-3, DENV is recognized by the cytoplasmic
helicases retinoic-acid-inducible gene I (RIG-I) and melanoma differentiation associated
gene 5 (MDA-5) to induce IFN-α/β (166). The interferon response to DENV triggers a
warning signal to adjacent non-infected cells and an autocrine induction of cellular
antiviral responses (167). IFN-α/β binds to its receptors on infected and neighboring cells
and activates a signaling pathway that eventually leads to the induction and production of
numerous antiviral proteins and pro-inflammatory cytokines (168). Another host cell type
that is important during initial DENV infection is the natural killer cell, the main
producers of IFN-γ (169). It is important to note that several studies have demonstrated
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that DENV viral proteins NS2A, NS4A, NS4B, and NS5 are able to inhibit the IFN-α
mediated innate antiviral response by blocking activation of the signal transducers and
activators of transcription (STAT) signaling pathway (170-173).
The major target cells for DENV, the monocytes and dendritic cells, are antigenpresenting cells (APCs) that are critical for stimulating cell mediated immunity. Cell
mediated immunity is comprised of two major subsets of T cells, CD4 and CD8. Little is
known about the role of CD8+ T cells during a DENV infection but it has recently been
revealed that the cytolitic effect of these cells is important in controlling a primary DENV
infection (174). It has also been reported, however that cellular immunity is not fully
activated during acute infections and the memory T cell activation during heterologous
secondary DENV infections results in a massive production of cytokines and chemokines
(175, 176). CD4+ T cells play a different role in the response to DENV by mediating
cytotoxicity and producing cytokines. CD4+ T cells also activate APCs and B cells.
The humoral response to DENV infection usually occurs approximately 5-6 days
post infection with DENV, with IgM antibodies typically produced first. While IgM
peaks at two weeks after onset, DENV specific IgG is detectible in patients after the first
week and continues to rise (153). The antibody response is mainly directed against the E
and PrM structural proteins on the surface of the virus (177, 178). There are is also
evidence that suggests that antibodies directed at the NS1 protein, which is expressed on
the surface of infected cells and is secreted from these cells as a soluble factor (177, 179,
180). It has been demonstrated that these antibodies can activate complement-mediated
lysis of DENV-infected cells and protect mice from DENV challenge (181-184).
However, anti-NS1 antibodies have been reported to be cross reactive with human
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platelets and endothelial cells, leading to increased vascular permeability. Antibodies to
all of the defined DENV epitopes have varying degrees of cross-reactivity to different
DENV serotypes as well as different neutralization potential.
Antibody neutralization of DENV occurs via multiple mechanisms. Antibodies
can bind to the virus and block binding to host cell receptors. Antibodies can also bind to
virus and be internalized with the virus, but block fusion with the endosomal membrane.
Another possibility is that antibodies specific for DENV virions bind to the incoming
virus and enhance its uptake into host cells via FcγR binding, thus is the case during
ADE. ADE occurs during secondary heterotypic DENV infections and is characteristic of
patients suffering from DHF or DSS. The tropism of dengue virus for monocytes,
macrophages and dendritic cells, all FcγR bearing cells, creates the opportunity for
DENV specific antibodies to enhance viral entry. During ADE, antibodies that are nonneutralizing or sub-neutralizing against a primary infecting virus remain active and bind
to the heterotypic secondary infecting virus or viral particle. Studies with anti-E protein
antibodies suggest that when virion opsonization is below the threshold necessary for
virus neutralization, these antibodies participate in ADE (185). The formation of a
antibody-virus complex occurs and this complex is shuttled to those FcγR bearing cells
(158, 185-188). This leads to an increase in the number of cells that are infected and an
increase in the number of virus particles produced per infected cell (189). DENV
infection through the mechanism of ADE can induce the production of IFN-α, TNF-α,
and IL-10 as well as upregulate costimulatory molecules CD40 and CD86 (190). The
activation of complement by antibody-virus complexes also contributes to the disease
state by activating complement, which induces temporal plasma leakage (191, 192).
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In patients with DHF or DSS, ADE is often accompanied by original antigenic
sin, a phenomenon wherein sequential exposure to closely a related virus reduces the
novel response to the secondary virus and impairs the development of immunological
memory. The hallmark of the pathogenesis of these two disease states is the loss of
endothelial integrity, which is assumed to be the result of an abnormal immune response
to the virus, the “cytokine storm” (143). It is believed by man scientists that original
antigenic sin is responsible for the cytokine storm. During a secondary heterotypic
infection low avidity memory T cells are re-activated and inefficient in clearing the new
viral infection. It has been demonstrated that these T cells have suboptimal degranulation,
altered cytokine production and cytolytic activity. These T cells are not only unable to
efficiently clear the DENV infection but they cause a massive immune activation (175,
193-195).
Figure 9 shows an integrated model describing the immunopathogenesis of severe
DENV infection. It is likely that many immunological processes contribute to DHF and
DSS (143).
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Other viral and host factors controlling DENV infection

genotypes.

Virus virulence

Glycosylation of E and NS1 proteins

Genotype differences

The addition of carbohydrates to viral proteins is important
for viral virulence [29, 169–171]. For example, glycosylation at position E Asn153 has been suggested to play a
role in stabilizing dimer interactions between E monomers
by partially occluding the fusion peptide [21]. Furthermore,
the addition of carbohydrates to E Asn67 have been
observed to be critical for virus particle production in
mammalian and mosquito cell lines [29]. Also, this carbohydrate group has been implicated to mediate binding of
the virus particle to DC-SIGN on DCs [172].

Low-fidelity replication together with natural-selection
processes have led to the development of multiple genotypes within each DENV serotype (see [156] for a great
review on this topic). Interestingly, several studies have
indicated that certain DENV-2 and DENV-3 genotypes are
more often associated with DHF [157–165]. For example,
the first outbreak of DHF in the Americas coincided with
the introduction of the DENV-2 Southeast Asia genotype.
Fig. 4 Immunopathogenesis of
severe dengue—an integrated
model

Figure 9. Immunopathogenesis of severe dengue – an integrated model.
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The development of passive immunotherapy to treat DENV infections remains an
elusive goal of many. In order to treat DENV effectively with antibody therapy it is
necessary to determine DENV specific neutralizing epitopes. Current research is
primarily focused on elucidating epitopes within the E protein. The E protein is the
principal surface component of the dengue virion and is composed of three domains (DI,
DII, and DIII) (196). DI is the central domain and contains non-neutralizing epitopes.
Several neutralizing epitopes have been found within the conserved fusion loop region in
DII and the lateral ridge and fusion loop of DIII (196-207). A smaller body of research
suggests that there are protective epitopes within PrM and some of the nonstructural
proteins, specifically NS1, NS3, and NS5 (196, 206, 208-213). All of the characterized
DENV epitopes have been revealed using either mammalian or murine antibodies, both
of which have reactive Fc portions. The problem with this trait is that if used for
treatment they have the ability to complex with virus and interact with FcγR on target
cells, monocytes, macrophages and dendritic cells, and potentially induce ADE.
In a recent study, Balsitis et al. verified using aglycosylated and F(ab’)2 DENV
specific IgG that the interaction between the Fc portion of the serotype cross-reactive
antibodies and the FcγR is required to induce ADE. Additionally they demonstrated that
the aglycosylated DENV-specific antibodies were as neutralizing as their naturally
glycosylated (or non-modified) variants, were incapable of inducing ADE, and were
therapeutic following a lethal, antibody-enhanced infection when administered up to 48
hours later (214). We, therefore, hypothesized that avian IgY, that do not interact with
mammalian FcγR, would provide a novel therapy for DENV induced disease.
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Preliminary studies with West Nile Virus IgY
There are many advantages to using IgY for the treatment of DENV infections.
One possibility is that IgY will be able to neutralize a viral infection in the absence of
ADE. IgY is also very well tolerated in humans, and can be produced in large quantities
very efficiently. Past research in our lab has exploited geese as a source of IgY. Initial
studies aimed to determine if the serum from West Nile Virus (WNV) immune geese
could protect against WNV infection in geese. Geese were given immune serum prior to
and post WNV infection and mortality was assessed. Of the ~10,000 geese per group
there was a ~65% reduction in mortality when administered as a prophylactic and ~62%
reduction in mortality when administered as a treatment (unpublished data Schiltz, Petell,
& Bradley). These experiments were repeated with purified anti-WNV IgY and similar
results were observed. Purified anti-WNV IgY was also tested in WNV infected golden
hamsters. All of the hamsters treated with the anti-WNV IgY survived and had viral titers
of zero, compared to the sham treated hamsters who had 100% mortality and ~65% viral
titer (unpublished data Schiltz, Petell, & Bradley).
DENV2 epitope mapping of goose-derived IgY: IgY and IgYΔFc
The aim of the current research study was to identify anti-DENV2 IgY protective
epitopes and determine the ability of these specific antibodies to treat DENV2 infections.
Epitope mapping was performed using 4 different viral proteins: E protein, PrM protein,
NS1, and NS3 with either anti-DENV2 IgY or anti-DENV2 IgYΔFc. Here we present
data suggesting that different populations of IgY recognize different DENV epitopes and
IgY recognizes epitopes uncharacterized for mammalian or murine IgG.
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Materials and Methods
Geese
Ten geese were vaccinated with 120 µg of Dengue Killed Virus (Dengue Type 2
Antigen, Microbix Biosystems Inc.) on Day 0 and 60 µg boost immunizations on week 2
and 4. Immunizations consisted of 2 x 200 µL subcutaneous injections at the back of the
neck in two different injection spots. The eggs were collected starting from week 4 after
the first immunization and stored at 4°C till further use.
Purification of IgY and IgY(DFc) from Goose Egg Yolk
Yolks were isolated and rinsed with water and then punctured to drain the
contents and diluted 1:10 with cold deionized water, stirred, and acidified to pH 5.0. The
diluted yolk was centrifuged at 10,000 x g for 30 minutes, and the supernatant was
filtered. In order to separate the full-length IgY from the transcriptionally truncated
IgYΔFc a sequential series of 30%, 40% and 50% ammonium sulfate were used. The
pellets were suspended in 50 mM Tris HCl pH 8.0. Further purification was achieved via
hydrophobic charge induction chromatography on 4-Mercapto-Ethyl-Pyridine-linked
(MEP) HyperCel sorbent (Pall Corporation) followed by buffer exchange.
Antibody Detection
The antibody activity of anti-DENV2 was determined by ELISA. Briefly,
microtiter plates were coated with 100 ml of the capture antigen (Dengue Type 2
Antigen, Microbix Biosystems Inc) and stored at 4°C overnight. After washing the plates
3 times with wash buffer (1X PBS, 0.05% Tween-20 (Fisher Scientific), they were
blocked with 400 mL per well of blocking buffer (0.25% BSA (Fisher Scientific), 0.05%
Tween-20 (Fisher Scientific)1X PBS) and incubated for 30 minutes at room temperature.
!

76!

!

The wells were washed 3 times with wash buffer and incubated with 100 mL of diluted
goose antibody and serially diluted down the plate in blocking buffer and incubated at
37°C for 30 minutes. Proper dengue control and Naïve control antibodies were included
as standards on each plate. The plates were washed 3 times with wash buffer and blocked
for 10 minutes at room temperature. Next, 100 mL of biotinylated rabbit anti-goose IgY
antibody was added to each well and incubated at 37°C for 30 minutes. After washing the
plates 3 times with wash buffer the wells were blocked for 10 minutes at room
temperature. Following this, 100 mL of diluted strepavidin-HRP antibody in blocking
buffer (1:2000) was added to each well and the plates were incubated at 37°C for 30
minutes. The plates were finally washed 3 times before adding 100 mL of prepared OPD
color substrate to each well and allowed to develop for 15 minutes at room temperature.
The reaction was terminated by adding 50 mL of 1N H2SO4, and the absorbance read in
BioTek plate reader at A490.
In Vitro Viral Neutralization and Antibody Dependent Enhancement studies
The neutralization and enhancement titers for anti-DENV2 and control purified
polyvalent IgY sera against DENV2 D2S10 were determined. D2S10 is a DENV2 strain
developed in the lab of Dr. Eva Harris in the Division of Infectious Diseases and
Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA
(215). Both neutralization and enhancement experiments were performed twice, each
time in duplicate. In brief, the sera were diluted to a starting concentration of 2.0 mg/mL.
Twelve 4-fold dilutions were mixed with equivalent volumes of DENV2 D2S10 for 45
minutes before infecting U937 DC-SIGN cells, a DENV-permissive monocytic cell line.
The cells were washed two hours following infection, and then fixed and stained for
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DENV E protein 24 hours later. The data was analyzed by flow cytometry, and the
dilution yielding 50% neutralization (NT50) was calculated using GraphPad PRISM.
To test for potential enhancement, the serum was diluted and mixed with DENV2
as described above and used to infect K562 cells, an erythroleukemic cell line that is not
naturally permissive for DENV infection, but can be infected via surface FcγRIIA when
DENV virions are coated with sub-neutralizing concentrations of anti-DENV antibody.
The cells were fixed, stained, and analyzed as described above 48 hours following
infection.
In Vivo anti-DENV2 IgY neutralization
The therapeutic potential of goose-derived anti-DENV2 IgY was tested using
conditions that cause 100% mortality in AG129 mice. Six-eight week old IFN-αβR-/- and
IFN-γR-/- (AG129) mice were administered a sub-lethal intravenous infection with
D2S10 (2x105 plaque forming units (PFU)). Twenty-four hours after infection, mice were
injected i.p. with the indicated amounts of polyclonal anti-DENV2 IgY or the positive
control mouse monoclonal antibody (MAb) E60 N297Q in a volume of 200 µL, or 200
µL of PBS as a negative control. Mice were followed for 10 days and observed for
morbidity and mortality twice daily. Anti-DENV2 IgYwas administered as 20, 100, or
500 µg per injection, control naïve IgY was administered as 500µg per injection, and the
positive control IgG E60 N297Q was administered as 20µg per injection.

Epitope mapping
Anti-DENV2 IgY epitopes were mapped on the E, PrM, NS1 and NS3 proteins
via peptide arrays. Specifically, each protein was covalently attached in 11 amino acid
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overlapping 15mer peptides to a microarray slide (JPT Innovative Peptide Solutions,
Berlin, Germany). All Pepstar™ microarray protocols were provided by JPT. Briefly, a
slide sandwich containing the microarray and a dummy slide was made, separated by
spacers, in order to increase and incubation environment. The primary antibody serum
was incubated on the slide at 4°C overnight in a moist environment. The slide was rinsed
5 times for 4 minutes each with T-TBS, then 5 times for 4 minutes each with ultra pure
water. The slide was incubated in the fluorescently labeled (Cy5) secondary antibody
solution (1µg/mL) for 45 minutes, washed 5 times with T-TBS, then 5 times with ultra
pure water, and dried using a dust free, oil free, high velocity canned air. Fluorescence
was measured at a pixel sized of 10µm using the Genepix™ 4000 microarray reader. The
signal intensity mean values were calculated for each sub-array and background corrected
values were used for interpretation in Microsoft excel. The microarray experiment was
repeated with each antibody type on three separate but identical slides; anti-DENV full
length IgY, anti-DENV IgYΔFc, and control naïve IgY.
Purification of DENV2 epitope specific IgY and IgYΔFc
Careful analysis of the epitope mapping data revealed several epitopes that were
recognized by either the IgY or IgYΔFc with at least 2x higher MFI than the naïve
control IgY. We selected peptides within the NS1 proteins to use for generating a
population of peptide/epitope specific IgY. This was carried out using an AminoLink
coupling resin Kit (Thermo Scientific). The AminoLink aldehyde activated agarose bead
resin was suspended by end over end mixing and then centrifuged within a 15 mL conical
at 1000 x g for 1 minute. Following, 2 mL of pH 7.2 coupling buffer was added to the
column and centrifuged at 1000 x g for 1 minute, this step was repeated once. The bottom
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of the column was capped and 2mL (1mg/mL) of the specific peptide solution was added
to the column (peptides were synthesized by GenScript). In a fume hood, 40 µL of
sodium cyanoborohydride solution was added to the column. The top cap was replaced
and the column was mixed by end over end mixing overnight at room temperature. The
next day the caps were removed and the column was centrifuged at 1000 x g for 1 minute
to collect the unbound peptide. The flow through was collected to determine coupling
efficiency. The column was washed with 2 mL quenching buffer and centrifuged at 1000
x g for 1 minute, this step was repeated once. Following this 2 mL of quenching buffer
and 40 µL of sodium cyanoborohydride was added to the column and the column was
mixed by end over end rocking for 30 minutes at room temperature to block the
remaining active sites. The column was then centrifuged at 1000 x g for 1 minute to
remove the quenching buffer. The column was washed 4 times with wash buffer and
centrifugation at 1000 x g for 1 minute each time. 2 mL of undiluted IgY or IgYΔFc was
added to each of the respective columns and the sample was allowed to enter the resin.
0.2 mL of binding/wash buffer was added to the column and the column mixed by end
over end rocking at room temperature for 1 hour. To wash the resin, 2mL of
binding/wash buffer was added and the column was centrifuged at 1000 x g for 1 minute,
this step was repeated once. The flow through was collected to determine binding
efficiency. The column washed 4 times with wash buffer. To elute the antibodies 2 mL of
elution buffer was added to the column and centrifuged at 1000 x g for 1 minute, this step
was repeated twice. The column was equilibrated with 4 mL wash buffer and stored at
4°C.
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Plaque reduction neutralization test (PRNT)
Baby hamster kidney (BHK) cells were obtained from ATCC and grown in
DMEM with 5% FBS and 1x pen/strep in a tissue culture flask at 37°C. Cells were plated
into 6 well tissue culture plates and incubated at 37°C and 5% CO2. Cells were allowed to
grow to be 95-100% confluent. On the day of the experiment 1:15,000 dilution of
DENV2 D2S10 was made and aliquoted in 2mL aliquots into sterile 15 mL conicals. 100
µL of each peptide specific antibody to be tested was added to the respective virus
aliquots and incubated at 37°C and 5% CO2 for one hour. Just prior to this the media in
the 6 well plates was aspirated and the cells were washed once with 2 mL/well of growth
media. The 2 mL DENV2 D2S10 – antibody mixtures were added to each well. Virus
only and media only wells were used for controls. The plate was incubated at 37°C and
5% CO2 for 90 minutes. The media was aspirated and 3 mL of 2% methylcellulose
overlay was added to each well. The plate was incubated for 7 days at 37°C and 5% CO2.
On day 7 the overlay was aspirated and 1 mL of buffered formalin (1 part 10% buffered
formalin to 1 part PBS) was added to each well and allowed to incubate at room
temperature for 30 minutes. The formalin was aspirated and crystal violet was added to
each well. The crystal violet was removed and the wells were washed with distilled
water. Plaques were counted to determine antibody neutralization capacity.
Results
Antibody characterization
Following the purification of anti-DENV2 IgY and ELISA was performed to
confirm the presence of DENV2 specific IgY and to determine the antibody titer. Egg
yolk titers are indicative of serum titers because antibodies are transferred from the serum
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of the laying hen to the egg yolk during embryogenesis. Of the 80 eggs that were
measured, the average serum titer was 1:850,000 with the highest titer being 1:3,800,000
(Figure 10).
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Figure 10. Anti-DENV2 IgY antibody titer in egg yolk. Egg yolks were collected from
geese immunized with DENV2 killed virus. Arrows indicate boost immunizations at 2
and 4 weeks post first immunization. Anti-Dengue IgY antibody titer did not differ
among weeks (ANOVA on ranks, p = 0.157). Data presented as mean ± SE. Sample sizes
presented within figure.
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In Vitro Viral Neutralization and Antibody Dependent Enhancement
Polyvalent anti-DENV2 IgY were purified from serum of DENV2-immunized
geese. These antibodies were tested for potential enhancement and neutralization in vitro.
Anti-DENV2 IgY was mixed with DENV2 D2S10 and used to infect U937 DC-SIGN
(neutralization) or K562 (enhancement) cells. The cells were washed, fixed, stained for
DENV E protein. The data was analyzed by flow cytometry. For the neutralization
experiment the dilution yielding 50% neutralization (NT50) was calculated using
GraphPad PRISM. The anti-DENV2 IgY serum NT50 was determined to be 1.0 and 2.6
µg/mL in two independent experiments (Figure 11). The control IgY serum did not yield
a measurable NT50 titer in either experiment. In the enhancement experiment, while the
positive control anti-DENV monoclonal antibody resulted in ~ 15% infection at its peak
enhancement titer, neither the anti-DENV IgY nor control sera were enhancing across
any dilution tested (figure 11).
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A.

B.

Figure 11. Anti-DENV2 purified IgY neutralizes but does not enhance DENV2 D2S10
in vitro. A) Anti-DENV2 IgY (NT50 2.6µg/mL), but not control, purified IgY neutralized
DENV2 D2S10. Relative percent infection is shown on the y-axis, and log reciprocal
antibody concentration on the x-axis. The data are representative of two independent
experiments. B) Neither anti-DENV2 IgY nor control purified IgY enhanced DENV2
D2S10, whereas control MAb E60 generated ~ 15% enhancement at the peak enhancing
titer. Percent infection is shown on the y-axis and log reciprocal antibody concentration
on the x-axis. These data are representative of two independent experiments.

!

85!

!

In Vivo anti-DENV2 IgY neutralization
AG129 mice were challenged with a lethal dose of D2S10 and the in vivo neutralization
capacity of anti-DENV2 was determined. In Figure 12, we have combined the results of
six different experiments using a lethal dose (1.0x107 PFU) of DENV2 D2S10. We
consistently observed therapeutic efficacy with 2 mg anti-DENV2 IgY (n=13)
administered 24 hours post-infection, similar to the 100% therapeutic protection observed
with our positive control, 20 mg of MAb E60-N297Q (n=6). However, 2 mg of control
IgY (n=16) provided 50% therapeutic protection. Therefore, we tested 1 mg of antiDENV2 IgY, which also provided 100% protection (n=8); however, administration of 1
mg of control IgY yielded 25% protection (n=4). These results indicate to us that some
non-specific protection may be provided by large amounts of goose antibodies regardless
of specificity, in this model. The dose of 500 mg anti-DENV2 IgY (n=6) provided 66%
protection, and the dose of 50 mg anti-DENV2 IgY (n=6) provided 33% protection,
whereas 50 mg of control IgY (n=2) provided no protection. The viral dose was lethal in
all the mice that received only PBS 24 hours post-infection (n=8).
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Figure 12. Therapeutic efficacy of anti-DENV2 in vivo. 6-8 week old AG129 mice were
administered a lethal dose (1X107 pfu) of DENV2 D2S10 i.v. in a volume of 100 mL. At
24 hours p.i. mice were injected one time i.p. with the indicated amounts of antibody in a
volume of 200 mL and 200mL of PBS was administered to a group of mice as a negative
control. Mice were followed for 10 days and observed for morbidity and mortality twice
daily. Number of mice per group is indicated.

!

87!

!

DENV2 IgY epitopes
Anti-DENV2 IgY epitopes were mapped on the E protein, PrM protein, and NS1
and NS3 proteins. Full length anti-DENV2 IgY and alternatively spliced anti-DENV2
IgY epitopes were compared to each other and to previously characterized anti-DENV2
IgG epitopes. Our results suggest that there are both similar and different epitopes
recognized by either full length or alternatively spliced anti-DENV2 IgY. Similarly, antiDENV2 IgY recognized different epitopes than anti-DENV2 IgG. We noticed that naïve
IgY recognized several of the same epitopes that both full length and alternatively spliced
IgY recognized, however there were epitopes recognized that were unique to either of the
anti-DENV2 IgY populations.
Heat maps were generated to display the epitope mapping data. Heat maps display
the MFI in a color gradient. The red color represents strong binding of our antibody to the
indicated peptide (Figures 13-16).
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Peptide
'ΔFc'IgY
Full'length
Naïve'IgY
AGVLWDVPSPPPV
=790
=451.3333333
=2031
LWDVPSPPPVGKA
=233.6666667
=337.6666667
=794.3333333
VPSPPPVGKAELE
=590.3333333
=170.6666667
=1533
PPPVGKAELEDGA
=385.3333333
=210.3333333
=563.3333333
VGKAELEDGAYRI
=177.3333333
=222.3333333
=702
AELEDGAYRIKQK
=365.6666667
=317
=628.3333333
EDGAYRIKQKGIL
=272.6666667
=162.6666667
=287
AYRIKQKGILGYS
5114.333333
6104.666667
12392
IKQKGILGYSQIG
483.6666667
731.6666667
12672
KGILGYSQIGAGV
=294
=172.3333333
1927.333333
LGYSQIGAGVYKE
=408
=72.33333333
1501.666667
SQIGAGVYKEGTF
=309.6666667
=87
=155
GAGVYKEGTFHTM
=559.6666667
=228.3333333
513
VYKEGTFHTMWHV
9180
12706
35916
EGTFHTMWHVTRG
7273.666667
6886
15503.66667
FHTMWHVTRGAVL
11986
12309.66667
22320.33333
MWHVTRGAVLMHK
4614.666667
2528.333333
3136
VTRGAVLMHKGKR
991.3333333
68.33333333
=593.6666667
GAVLMHKGKRIEP
=523
=240
=645
LMHKGKRIEPSWA
=273.3333333
=247.6666667
283.6666667
KGKRIEPSWADVK
=349.3333333
=271
=1121.666667
RIEPSWADVKKDL
=360.6666667
=224.6666667
=1663.333333
PSWADVKKDLISY
=416
=228.3333333
=592.6666667
ADVKKDLISYGGG
=467.3333333
=405
=1292.333333
KKDLISYGGGWKL
13116.66667
4399
22218
LISYGGGWKLEGE
8240.333333
685
8391
YGGGWKLEGEWKE
8450.333333
525.3333333
12053.33333
GWKLEGEWKEGEE
1978.333333
=99.33333333
=594
LEGEWKEGEEVQV
=188
=100
834.6666667
EWKEGEEVQVLAL
=486.6666667
=137.3333333
=1304.666667
EGEEVQVLALEPG
=361.6666667
=228
=514.3333333
EVQVLALEPGKNP
=284.3333333
=254
=941
VLALEPGKNPRAV
=541.6666667
=356.6666667
=994
LEPGKNPRAVQTK
=432.3333333
=312.3333333
=992.6666667
GKNPRAVQTKPGL
=418.6666667
=107.6666667
=1627
PRAVQTKPGLFKT
=386
=285.3333333
=877
VQTKPGLFKTNAG
=371.3333333
=341
=808.3333333
KPGLFKTNAGTIG
=437.3333333
=288.6666667
=997.6666667
LFKTNAGTIGAVS
=190
=189.6666667
=1454.333333
TNAGTIGAVSLDF
843.3333333
435.6666667
1442
GTIGAVSLDFSPG
=317.6666667
=244.3333333
=570
GAVSLDFSPGTSG
=322
=180
=1096.666667
SLDFSPGTSGSPI
276.6666667
=164.6666667
=1403.333333
FSPGTSGSPIIDK
=357.3333333
=200
=1739.333333
GTSGSPIIDKKGK
=714
=409
=1118.666667
GSPIIDKKGKVVG
=397
=369.3333333
=892.3333333
IIDKKGKVVGLYG
=196.3333333
196
8924.333333
KKGKVVGLYGNGV
=222.6666667
=111.3333333
=523
KVVGLYGNGVVTR
=149.3333333
83
2116
GLYGNGVVTRSGA
=399.6666667
=397
=751.6666667
GNGVVTRSGAYVS
=189.6666667
=131.6666667
=406.3333333
VVTRSGAYVSAIA
1159
693
4613.333333
RSGAYVSAIAQTE
=228
=188.3333333
=543.6666667
AYVSAIAQTEKSI
=361.6666667
=147.6666667
=615.6666667
SAIAQTEKSIEDN
=274.3333333
=218.6666667
=794
AQTEKSIEDNPEI
=422
=181.3333333
=807
EKSIEDNPEIEDD
=321.6666667
=185.6666667
=1630.666667
IEDNPEIEDDIFR
=468.6666667
=299.6666667
=744.3333333
NPEIEDDIFRKRK
=369.3333333
=226
=1322
IEDDIFRKRKLTI
401.6666667
864.3333333
5622
DIFRKRKLTIMDL
=443
=202
713
RKRKLTIMDLHPG
=264
=140.3333333
=74
KLTIMDLHPGAGK
=276
=15.66666667
=513
IMDLHPGAGKTKR
=529
=331.6666667
=327
LHPGAGKTKRYLP
=372.3333333
=277
203.6666667
GAGKTKRYLPAIV
=389.3333333
=138.6666667
198
KTKRYLPAIVREA
=469
=243.3333333
722.6666667
RYLPAIVREAIKR
4622
6826.333333
2101.666667
PAIVREAIKRGLR
3076.333333
1940
=331.3333333
VREAIKRGLRTLI
2066.666667
1483.666667
=791.3333333
AIKRGLRTLILAP
1283.333333
1248.666667
956
RGLRTLILAPTRV
578
331
341
RTLILAPTRVVAA
135.3333333
=39.66666667
2615
ILAPTRVVAAEME
=479
=288.6666667
=2535
PTRVVAAEMEEAL
=370.3333333
=260.3333333
=2202
VVAAEMEEALRGL
=434
=275
=1909
AEMEEALRGLPIR
=385.3333333
=284.6666667
=1297.333333
EEALRGLPIRYQT
=471
=316.6666667
=1024
LRGLPIRYQTPAI
96.66666667
249.6666667
3307
LPIRYQTPAIRAE
=249.6666667
=169.3333333
=900.6666667
RYQTPAIRAEHTG
=357
=250.3333333
=1688.333333
TPAIRAEHTGREI
=381
=134.3333333
=1306
IRAEHTGREIVDL
=162.6666667
=151.6666667
=573
EHTGREIVDLMCH
=253.3333333
=277.3333333
=666.6666667
GREIVDLMCHATF
595.6666667
952.3333333
4307
IVDLMCHATFTMR
4507
3854.666667
4834
LMCHATFTMRLLS
5010.666667
3615.666667
3899
HATFTMRLLSPVR
5103.666667
6220
4262.666667
FTMRLLSPVRVPN
1807
1790.666667
5027.333333
RLLSPVRVPNYNL
5851
7695
11611.66667
SPVRVPNYNLIIM
=56.66666667
=94
1042
RVPNYNLIIMDEA
=201.3333333
=192.6666667
=542.3333333
NYNLIIMDEAHFT
124.3333333
17.33333333
3546
LIIMDEAHFTDPA
=421
=263.6666667
=1138.666667
MDEAHFTDPASIA
=408.6666667
=283.3333333
=1108
AHFTDPASIAARG
=581
=311
=1664.666667
TDPASIAARGYIS
553.6666667
276.3333333
3024.666667
ASIAARGYISTRV
1965.333333
2024.333333
3870.333333
AARGYISTRVEMG
599.6666667
440
1976.333333
GYISTRVEMGEAA
=16.66666667
59.33333333
=139.6666667
STRVEMGEAAGIF
=208.3333333
=18.33333333
=11.66666667
VEMGEAAGIFMTA
=207.6666667
=158
=1414.666667
GEAAGIFMTATPP
=393.3333333
=307.3333333
=561.3333333
AGIFMTATPPGSR
=307.3333333
=205
=124.3333333
FMTATPPGSRDPF
=324
=199.3333333
1.666666667

Peptide
ATPPGSRDPFPQS
PGSRDPFPQSNAP
RDPFPQSNAPIMD
FPQSNAPIMDEER
SNAPIMDEEREIP
PIMDEEREIPERS
DEEREIPERSWSS
REIPERSWSSGHE
PERSWSSGHEWVT
SWSSGHEWVTDFK
SGHEWVTDFKGKT
EWVTDFKGKTVWF
TDFKGKTVWFVPS
KGKTVWFVPSIKA
TVWFVPSIKAGND
FVPSIKAGNDIAA
SIKAGNDIAACLR
AGNDIAACLRKNG
DIAACLRKNGKKV
ACLRKNGKKVIQL
RKNGKKVIQLSRK
GKKVIQLSRKTFD
VIQLSRKTFDSEY
LSRKTFDSEYVKT
KTFDSEYVKTRTN
DSEYVKTRTNDWD
YVKTRTNDWDFVV
TRTNDWDFVVTTD
NDWDFVVTTDISE
DFVVTTDISEMGA
VTTDISEMGANFK
DISEMGANFKAER
EMGANFKAERVID
ANFKAERVIDPRR
KAERVIDPRRCMK
RVIDPRRCMKPVI
DPRRCMKPVILTD
RCMKPVILTDGEE
KPVILTDGEERVI
ILTDGEERVILAG
DGEERVILAGPMP
ERVILAGPMPVTH
ILAGPMPVTHSSA
GPMPVTHSSAAQR
PVTHSSAAQRRGR
HSSAAQRRGRIGR
AAQRRGRIGRNPK
RRGRIGRNPKNEN
RIGRNPKNENDQY
RNPKNENDQYIYM
KNENDQYIYMGEP
NDQYIYMGEPLEN
YIYMGEPLENDED
MGEPLENDEDCAH
PLENDEDCAHWKE
NDEDCAHWKEAKM
DCAHWKEAKMLLD
HWKEAKMLLDNIN
EAKMLLDNINTPE
MLLDNINTPEGII
DNINTPEGIIPSM
NTPEGIIPSMFEP
EGIIPSMFEPERE
IPSMFEPEREKVD
MFEPEREKVDAID
PEREKVDAIDGEY
EKVDAIDGEYRLR
DAIDGEYRLRGEA
DGEYRLRGEARKT
YRLRGEARKTFVD
RGEARKTFVDLMR
ARKTFVDLMRRGD
TFVDLMRRGDLPV
DLMRRGDLPVWLA
RRGDLPVWLAYRV
DLPVWLAYRVAAE
VWLAYRVAAEGIN
AYRVAAEGINYAD
VAAEGINYADRRW
EGINYADRRWCFD
NYADRRWCFDGIK
DRRWCFDGIKNNQ
WCFDGIKNNQILE
DGIKNNQILEENV
KNNQILEENVEVE
QILEENVEVEIWT
EENVEVEIWTKEG
VEVEIWTKEGERK
EIWTKEGERKKLK
TKEGERKKLKPRW
GERKKLKPRWLDA
KKLKPRWLDARIY
KPRWLDARIYSDP
WLDARIYSDPLAL
ARIYSDPLALKEF
YSDPLALKEFKEF
PLALKEFKEFAAG
ALKEFKEFAAGRK

'ΔFc'IgY

=365
=333.3333333
=308
261
=436
=364
=370.3333333
=362.6666667
=440.6666667
=547.6666667
=376.6666667
6326.666667
151.6666667
229.3333333
=187
=211.6666667
=442
=296.6666667
=156.6666667
250.3333333
=329.6666667
606.3333333
430.3333333
=76
=282.3333333
=334.6666667
56.66666667
=259
=215.3333333
=342.3333333
=359
=269.3333333
=255
=431.6666667
=589.6666667
=348
=328
=305
=379.6666667
=248.3333333
=518.3333333
=260.6666667
=382.6666667
=302.6666667
=179.6666667
=321.3333333
=485
=507.3333333
=401.3333333
=436.6666667
=426
=412
=389.6666667
=322.6666667
=360.3333333
=375.6666667
=498.6666667
=355
=361
=305.3333333
=404.3333333
=372
=236.6666667
=182.6666667
=229
=278.6666667
=225.6666667
=259
=331
=101
477.6666667
478
=101.6666667
=313.6666667
=23.66666667
321.3333333
256.3333333
=146.6666667
155.3333333
=250.3333333
=149.6666667
=319.3333333
=172
=287.6666667
=34.33333333
=446.3333333
=152.6666667
=432.6666667
=155.3333333
=306.3333333
=187
11384.66667
=96.66666667
152.3333333
=233.6666667
=259
=319.6666667
33

Full'length
Naïve'IgY
=237.6666667
=1094
=213.3333333
=847.3333333
=176.3333333
=1848.666667
=136.6666667
=442.3333333
=273.3333333
=797.6666667
=272.6666667
=709.3333333
=217.3333333
=1590
=274.3333333
=1462
=329
=1415.333333
=286.3333333
=836.3333333
=256.3333333
=911.6666667
10916
27990
1001.666667
9102.666667
107.6666667
10894.33333
=136.6666667
=740
=155
352.3333333
=139.6666667
=672
=182.6666667
=1122.333333
=181
=1250
96.66666667
623
=205
=2354
287.3333333
4233.666667
843
8280
=20.66666667
=497
=182.3333333
=1615.333333
=245.6666667
=991
640.3333333
8597.333333
=182.6666667
=873.3333333
=178
=1133
=266.6666667
=657.3333333
=197.3333333
=1828.666667
=172
=744
=275.3333333
=1105
=390.6666667
=1429
=381.6666667
=1055.666667
=296.3333333
=1356
=267.3333333
=1420.333333
=274.3333333
=1199.333333
=165
=1679.666667
=222.3333333
=1050
=268.3333333
=1060
=124.3333333
=1071.666667
=257.3333333
=793.3333333
=283.6666667
=648
=182.6666667
=665.6666667
=217
=1291
=382.3333333
=876.3333333
=459.3333333
=805.6666667
=241
=547.6666667
=324
=421.6666667
=340.6666667
=676.3333333
=368.6666667
=1211
=232
=1075
=259.3333333
=794
=225.6666667
=713.3333333
=224.6666667
=1041.666667
=261.6666667
=1003
=243.3333333
=1617.333333
=221.6666667
=1411.333333
=128.6666667
=1368
=303.3333333
=1032.666667
=346
=1252.666667
=156.3333333
=904.3333333
=185.6666667
=1135.666667
=190.6666667
=798
=148
=1991.666667
=132.6666667
=1209.333333
=116.6666667
=1929
=211
=2014.333333
6.333333333
24.66666667
668
1832.333333
368.6666667
147.6666667
=74.66666667
916.3333333
=244.3333333
=338
65.33333333
434.6666667
1001
9223.666667
267.6666667
2792.666667
=32
2555
510
4630
=38.66666667
2241.666667
=74
2036.333333
=230.6666667
=53.66666667
=94.33333333
=1041.333333
=107.3333333
=828.6666667
=28
=703
=195.6666667
1002
=201.6666667
=1170
=166
=414.3333333
=275.3333333
=1438.666667
=183
=307
=151.3333333
=395
14187
15821.33333
=56.66666667
2573.333333
970.3333333
7718.666667
=131.6666667
733
=118.3333333
1714
=217.3333333
925.6666667
95.33333333
19.33333333

Figure 13. Identification of DENV2 NS3 epitopes. Amino acid sequence for NS3 was
used to make 15-mer peptides for microarray slide. Slides were incubated with antiDENV2 IgYΔFc, anti-DENV2 IgY full length, or naïve control IgY. Reactivity is
measured based on a spectrum ranging from no reactivity in black to high reactivity in
red. Values represent MFI-background.
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Peptide
'ΔFc'IgY
Full'length
Naïve'IgY
IGISNRDFVEGVS
<205
<126.3333333
<1704.666667
SNRDFVEGVSGGS
<410
<214.6666667
<979
DFVEGVSGGSWVD
<183.3333333
344.3333333
3316.666667
EGVSGGSWVDIVL
532
527.6666667
1706.666667
SGGSWVDIVLEHG
1835.333333
118.6666667
528
SWVDIVLEHGSCV
163.6666667
<135
81.66666667
DIVLEHGSCVTTM
<380.6666667
<234.6666667
<1562.666667
LEHGSCVTTMAKN
<195
<200
<1792
GSCVTTMAKNKPT
<327.6666667
<276
<960
VTTMAKNKPTLDF
<75.33333333
<221
<1649.333333
MAKNKPTLDFELI
<143.6666667
299.6666667
1171.333333
NKPTLDFELIKTE
<106.3333333
34
<1113
TLDFELIKTEAKQ
82
43.33333333
726
FELIKTEAKQSAT
<152.6666667
<123.6666667
<354.3333333
IKTEAKQSATLRK
133.3333333
<119
<348.3333333
EAKQSATLRKYCI
467
375.6666667
2203.333333
QSATLRKYCIEAK
1074.666667
967
1416
TLRKYCIEAKLTN
549.6666667
2469.333333
2711.333333
KYCIEAKLTNTTT
<159.6666667
1202.666667
<649.6666667
IEAKLTNTTTESR
<240
<105
<523
KLTNTTTESRCPT
<382
<285.6666667
<674.3333333
NTTTESRCPTQGE
<436
<258
<754.6666667
TESRCPTQGEPSL
<211.6666667
<203.6666667
<1709
RCPTQGEPSLNEE
<248.3333333
<214.6666667
<832.6666667
TQGEPSLNEEQDK
<262
<206.3333333
<1732.333333
EPSLNEEQDKRFV
612.6666667
<29
<986.3333333
LNEEQDKRFVCKH
<168.3333333
<277.3333333
<716
EQDKRFVCKHSMV
2038.666667
421.3333333
5295
KRFVCKHSMVDRG
<219.6666667
<198.6666667
<613.3333333
VCKHSMVDRGWGN
<352.3333333
<267.3333333
<645.3333333
HSMVDRGWGNGCG
<396.6666667
<285.6666667
<1388.666667
VDRGWGNGCGLFG
<323
<162.3333333
722
GWGNGCGLFGKGG
<162.6666667
<179.6666667
<474
NGCGLFGKGGIVT
<32.33333333
<48
1490.666667
GLFGKGGIVTCAM
<523.6666667
<277
<161.6666667
GKGGIVTCAMFTC
<231
<128
979.3333333
GIVTCAMFTCKKD
<360.3333333
<187
1313.666667
TCAMFTCKKDMKG
<454
<380.3333333
<895.6666667
MFTCKKDMKGEVV
<281
<270.3333333
<1093
CKKDMKGEVVQPE
<505
<463
<1532
DMKGEVVQPENLE
1649.333333
<184.6666667
<885
GEVVQPENLEYTI
5304.666667
224.3333333
<874.3333333
VQPENLEYTIVIT
749
307.6666667
<27
ENLEYTIVITPHS
118.3333333
75.33333333
<362.3333333
EYTIVITPHSGEE
<323.3333333
<292.3333333
<1039.333333
IVITPHSGEEHAV
774.3333333
22
<759.6666667
TPHSGEEHAVGND
<53
<190.3333333
<501
SGEEHAVGNDTGK
<251.6666667
<144.3333333
<912
EHAVGNDTGKHGK
52
<200
<1301
VGNDTGKHGKEIK
<269
<217
<928.3333333
DTGKHGKEIKITP
<80.33333333
<123
<1342.333333
KHGKEIKITPQSS
<223
<218.3333333
<1321.333333
KEIKITPQSSITE
<276.3333333
<205
<923
KITPQSSITEAEL
<264
<217.6666667
<938
PQSSITEAELTGY
<305
<105.3333333
<936.3333333
SITEAELTGYGTV
<243
<177.6666667
<969.3333333
EAELTGYGTVTME
<197
<167
<1789.666667
LTGYGTVTMECSP
<229.6666667
<157.6666667
<662.6666667
YGTVTMECSPRTG
<369.6666667
<259.3333333
<1706.666667
VTMECSPRTGLDF
<286.3333333
<155.6666667
<1165.666667
ECSPRTGLDFNEM
<245
<197.3333333
<1278.333333
PRTGLDFNEMVLL
<52.33333333
192.3333333
1698.333333
GLDFNEMVLLQME
<152.6666667
<93
173.6666667
FNEMVLLQMENKA
<177.3333333
<197.3333333
<438.6666667
MVLLQMENKAWLV
837.3333333
462
1886.333333
LQMENKAWLVHRQ
1538.666667
1693.666667
10980
ENKAWLVHRQWFL
12062.33333
12182
20134.66667
AWLVHRQWFLDLP
10184
12098.33333
33207.33333
VHRQWFLDLPLPW
21589.33333
17183
43312.66667
QWFLDLPLPWLPG
931
953.6666667
3694
LDLPLPWLPGADT
<48
26.66666667
1473.666667
PLPWLPGADTQGS
<295.6666667
<198.6666667
<602
WLPGADTQGSNWI
31.33333333
<98
1351.666667
GADTQGSNWIQKE
<323.6666667
<222.3333333
<768.3333333
TQGSNWIQKETLV
<289
<231.6666667
<1447.333333
SNWIQKETLVTFK
147
240
1736.666667
IQKETLVTFKNPH
<262.6666667
<229
<1104.666667
ETLVTFKNPHAKK
<124.3333333
<184.6666667
<148.6666667
VTFKNPHAKKQDV
<432
<252.6666667
<703.6666667
KNPHAKKQDVVVL
376.6666667
108.6666667
<25
HAKKQDVVVLGSQ
<138.3333333
<97
<434
KQDVVVLGSQEGA
<266.3333333
<229.3333333
<1343.333333
VVVLGSQEGAMHT
<297
<189
<1626.666667
LGSQEGAMHTALT
<421
<264
<2008.666667
QEGAMHTALTGAT
<138.3333333
<165
<804
AMHTALTGATEIQ
<364
<119.3333333
<812.3333333
TALTGATEIQMSS
<628.6666667
<281.6666667
<313.3333333
TGATEIQMSSGNL
<360.6666667
<171.6666667
<621

Peptide
TEIQMSSGNLLFT
QMSSGNLLFTGHL
SGNLLFTGHLKCR
LLFTGHLKCRLRM
TGHLKCRLRMDKL
LKCRLRMDKLQLK
RLRMDKLQLKGMS
MDKLQLKGMSYSM
LQLKGMSYSMCTG
KGMSYSMCTGKFK
SYSMCTGKFKVVK
MCTGKFKVVKEIA
GKFKVVKEIAETQ
KVVKEIAETQHGT
KEIAETQHGTIVI
AETQHGTIVIRVQ
QHGTIVIRVQYEG
TIVIRVQYEGDGS
IRVQYEGDGSPCK
QYEGDGSPCKIPF
GDGSPCKIPFEIM
SPCKIPFEIMDLE
KIPFEIMDLEKRH
FEIMDLEKRHVLG
MDLEKRHVLGRLI
EKRHVLGRLITVN
HVLGRLITVNPIV
GRLITVNPIVTEK
ITVNPIVTEKDSP
NPIVTEKDSPVNI
VTEKDSPVNIEAE
KDSPVNIEAEPPF
PVNIEAEPPFGDS
IEAEPPFGDSYII
EPPFGDSYIIIGV
FGDSYIIIGVEPG
SYIIIGVEPGQLK
IIGVEPGQLKLNW
VEPGQLKLNWFKK
GQLKLNWFKKGSS
KLNWFKKGSSIGQ
WFKKGSSIGQMLE
KGSSIGQMLETTM
SIGQMLETTMRGA
QMLETTMRGAKRM
ETTMRGAKRMAIL
MRGAKRMAILGDT
AKRMAILGDTAWD
MAILGDTAWDFGS
LGDTAWDFGSLGG
TAWDFGSLGGVFT
DFGSLGGVFTSIG
SLGGVFTSIGKAL
GVFTSIGKALHQV
TSIGKALHQVFGA
GKALHQVFGAIYG
LHQVFGAIYGAAF
VFGAIYGAAFSGV
AIYGAAFSGVSWT
GAAFSGVSWTMKI
FSGVSWTMKILIG
VSWTMKILIGVII
TMKILIGVIITWI
ILIGVIITWIGMN
GVIITWIGMNSRS
ITWIGMNSRSTSL
IGMNSRSTSLSVS
NSRSTSLSVSLVL
STSLSVSLVLVGV
LSVSLVLVGVVTL
SLVLVGVVTLYLG
LVGVVTLYLGVMV
GVVTLYLGVMVQA

'ΔFc'IgY

<114
2285.666667
7286.666667
8181.333333
3312.666667
736
77
2103.666667
384.6666667
5106.666667
2136.333333
<34
<329.3333333
<492
<15.66666667
<288.3333333
412.6666667
<183
<268.3333333
<366.6666667
<306.3333333
<452.3333333
<367
<373.6666667
837.3333333
2990
156.3333333
<508
<159
<70.33333333
<150
163.6666667
<317.6666667
<404.3333333
383
<224.6666667
<723
<305
2735.666667
164
537.3333333
2336.333333
<427.3333333
<321.3333333
<127.3333333
586.6666667
<527.6666667
<257.6666667
<163.3333333
<290
168.6666667
<131
<582.3333333
<9
363
5134.333333
813
238
<71.33333333
87.33333333
2774
178.6666667
155.3333333
<16.33333333
<355
<426
<331.6666667
<186.3333333
548
107
<600
904.6666667
<321.6666667

Full'length

<23
3923.666667
5230.666667
7540.666667
629.3333333
660
65.66666667
1543.666667
302.6666667
3678.333333
358
<203.6666667
<200.3333333
<85
<21.66666667
<265.3333333
<76.66666667
<136.6666667
<183.3333333
<214.3333333
<250.6666667
<292.3333333
<263.3333333
<227.6666667
3668.333333
3651.333333
708.6666667
<349.3333333
<235
633.6666667
<108.3333333
<42
<299
<240
<4.666666667
475
<289.3333333
1113
2675.333333
42.66666667
<100.3333333
41
<324.6666667
<320
<202.6666667
24.33333333
<262.3333333
<212.3333333
79.33333333
<210.3333333
1045.333333
<18
<278.3333333
<39.66666667
187
4906.333333
698.3333333
195.6666667
180
197.6666667
2295.666667
222.6666667
175.3333333
41.33333333
<230.6666667
<298.3333333
<243.6666667
49.66666667
735.6666667
140.3333333
<332.6666667
427.3333333
<98.33333333

Naïve'IgY
<20.33333333
11835
14341
8165
337.6666667
919
94.66666667
4902.666667
3306.333333
<56
267
<120.6666667
<199.3333333
<1474
88.33333333
<971.6666667
<712.6666667
<1792
<1558.333333
<746.3333333
<1261
<1633.333333
<1362.666667
<940
2100.666667
4237.666667
2966
<706.6666667
<586.6666667
821.6666667
<587.3333333
<367.3333333
<967.3333333
<2
3911
3592.666667
218.6666667
3925.666667
10662.66667
614.3333333
52
<386.3333333
<873.6666667
<817.6666667
<1042.666667
501
<1016.666667
<2453.333333
3234.666667
<1025.666667
12727.66667
2520.333333
<2060.666667
777.3333333
<1071.333333
17752.33333
3921.666667
2313.333333
5484
2786.666667
5333.666667
959.6666667
1799.666667
172.6666667
<341.3333333
<1392.333333
<1339.666667
29.33333333
1613
243.6666667
<831.6666667
1827.666667
521

Figure 14. Identification of DENV2 E protein epitopes. Amino acid sequence for E
protein was used to make 15-mer peptides for microarray slide. Slides were incubated
with anti-DENV2 IgYΔFc, anti-DENV2 IgY full length, or naïve control IgY. Reactivity
is measured based on a spectrum ranging from no reactivity in black to high reactivity in
red. Values represent MFI-background.
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Peptide
'ΔFc'IgY
Full'length
Naïve'IgY
FHLTTRNGEPHMI
=199
=109
1041.333333
TTRNGEPHMIVSR
=342.3333333
=160.3333333
=306.6666667
NGEPHMIVSRQEK
=365.3333333
=267.3333333
=1050.666667
PHMIVSRQEKGKS
=154.6666667
=101.3333333
=710
IVSRQEKGKSLLF
2816.666667
2995.666667
5313
RQEKGKSLLFKTG
=286
=106
=620
KGKSLLFKTGDGV
=363
=185.6666667
=681.3333333
SLLFKTGDGVNMC
=321.3333333
=105.6666667
=789.6666667
FKTGDGVNMCTLM
=262
=177.3333333
=536.6666667
GDGVNMCTLMAMD
=140.6666667
=127
=177.3333333
VNMCTLMAMDLGE
=480.6666667
=287
=1031.666667
CTLMAMDLGELCE
=367
=98
=1151.333333
MAMDLGELCEDTI
=566.3333333
=311.6666667
=1313.666667
DLGELCEDTITYK
=450.3333333
=285
=1301.333333
ELCEDTITYKCPL
=244
=146
=27.66666667
EDTITYKCPLLRQ
=385.3333333
=250
=1272.666667
ITYKCPLLRQNEP
=262.6666667
=203.6666667
=882
KCPLLRQNEPEDI
=288
=242.3333333
=886.6666667
LLRQNEPEDIDCW
13.33333333
=141.3333333
=955
QNEPEDIDCWCNS
=363.6666667
=207.6666667
=1026
PEDIDCWCNSTST
=331.3333333
=164
=1094.666667
IDCWCNSTSTWVT
4.666666667
133
3584
WCNSTSTWVTYGT
153
184
7348.666667
STSTWVTYGTCTT
=223
17
3629.666667
TWVTYGTCTTTGE
=701.3333333
=402.6666667
=17
TYGTCTTTGEHRR
=324.6666667
=276.3333333
369.3333333
TCTTTGEHRREKR
=419.6666667
=191.3333333
=1304.666667
TTGEHRREKRSVA
=282.6666667
=171.3333333
90
EHRREKRSVALVP
=277.6666667
=219.6666667
=609
REKRSVALVPHVG
=244
=152.6666667
=58.33333333
RSVALVPHVGMGL
945.6666667
1990.333333
4661
ALVPHVGMGLETR
=37.66666667
=3
391
PHVGMGLETRTET
=374.3333333
=249.3333333
=1069
GMGLETRTETWMS
=192
=54.33333333
1846.333333
LETRTETWMSSEG
=253
=220.3333333
=530
RTETWMSSEGAWK
581.3333333
616
7376
TWMSSEGAWKHAQ
=217.6666667
=197
=48
SSEGAWKHAQRIE
=335
=246
327.3333333
GAWKHAQRIETWI
825.6666667
1857
9546.666667
KHAQRIETWILRH
1415
1357
7776
QRIETWILRHPGF
7199.333333
8871.666667
18426.66667
ETWILRHPGFTIM
10920.33333
13709.66667
24216.66667
ILRHPGFTIMAAI
21.66666667
46.33333333
588
HPGFTIMAAILAY
571
473
2872
FTIMAAILAYTIG
524.3333333
317
1719.333333
MAAILAYTIGTTH
160.3333333
27.66666667
2562
ILAYTIGTTHFQR
12177
12438
18925.66667
YTIGTTHFQRALI
365
181.3333333
11275.33333
GTTHFQRALIFIL
387
584.3333333
1013
HFQRALIFILLTA
=203
=83.66666667
181.6666667
RALIFILLTAVAP
=440
=265
=536
IFILLTAVAPSMT
=179.3333333
24
150.6666667

Figure 15. Identification of DENV2 PrM epitopes. Amino acid sequence for PrM was
used to make 15-mer peptides for microarray slide. Slides were incubated with antiDENV2 IgYΔFc, anti-DENV2 IgY full length, or naïve control IgY. Reactivity is
measured based on a spectrum ranging from no reactivity in black to high reactivity in
red. Values represent MFI-background.
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Peptide
DSGCVVSWKNKEL
CVVSWKNKELKCG
SWKNKELKCGSGI
NKELKCGSGIFIT
LKCGSGIFITDNV
GSGIFITDNVHTW
IFITDNVHTWTEQ
TDNVHTWTEQYKF
VHTWTEQYKFQPE
WTEQYKFQPESPS
QYKFQPESPSKLA
FQPESPSKLASAI
ESPSKLASAIQKA
SKLASAIQKAHEE
ASAIQKAHEEGIC
IQKAHEEGICGIR
AHEEGICGIRSVT
EGICGIRSVTRLE
CGIRSVTRLENLM
RSVTRLENLMWKQ
TRLENLMWKQITP
ENLMWKQITPELN
MWKQITPELNHIL
QITPELNHILSEN
PELNHILSENEVK
NHILSENEVKLTI
LSENEVKLTIMTG
NEVKLTIMTGDIK
KLTIMTGDIKGIM
IMTGDIKGIMQAG
GDIKGIMQAGKRS
KGIMQAGKRSLRP
MQAGKRSLRPQPT
GKRSLRPQPTELK
SLRPQPTELKYSW
PQPTELKYSWKTW
TELKYSWKTWGKA
KYSWKTWGKAKML
WKTWGKAKMLSTE
WGKAKMLSTESHN
AKMLSTESHNQTF
LSTESHNQTFLID
ESHNQTFLIDGPE
NQTFLIDGPETAE
FLIDGPETAECPN
DGPETAECPNTNR
ETAECPNTNRAWN
ECPNTNRAWNSLE
NTNRAWNSLEVED
RAWNSLEVEDYGF
NSLEVEDYGFGVF
EVEDYGFGVFTTN
DYGFGVFTTNIWL
FGVFTTNIWLKLR
FTTNIWLKLREKQ
NIWLKLREKQDVF
LKLREKQDVFCDS
REKQDVFCDSKLM

'ΔFc'IgY
Full'length
Naïve'IgY
?253.6666667
?260.3333333
?606.6666667
?489.6666667
?311
?149
?342.3333333
?322
?1085
?234.6666667
?117.3333333
996
?130.3333333
?174
?334
1.666666667
570
7119.333333
?107.3333333
?77.33333333
937.3333333
56.33333333
474
10449.66667
?315.3333333
?196.6666667
?831.3333333
?198.6666667
?141
?1087.666667
?266.6666667
?173.6666667
?761.6666667
?30.33333333
?154.3333333
?586.6666667
?312
?216.3333333
?1041.333333
?318.6666667
?200.3333333
?1816.333333
?301.3333333
?154.3333333
?874.3333333
?350.6666667
?177.3333333
?1538.333333
?364.3333333
?215.3333333
?1584.666667
?282.3333333
?199
?359
?230.6666667
?155
?2179.666667
5.666666667
351.6666667
?81
?339.6666667
?249
?733
?272
?193
?880.3333333
?274.6666667
131
2442.666667
?324.6666667
?132.6666667
?1600
?316
?228.3333333
?843.6666667
86.66666667
71
682
251.3333333
?93.33333333
?113
?301.3333333
?201.3333333
?519.6666667
47.66666667
?70.66666667
844.6666667
?285.3333333
?311.6666667
?590
64.66666667
?39.33333333
121.3333333
1521.333333
589
1406.333333
?360
?189
?670
?429
?359.3333333
?1185
?214.6666667
2
5042.333333
1741
3637
20900
?23.33333333
352.6666667
11510.33333
2857
1723.333333
4968.333333
?507.6666667
?309
?1418.333333
?331
?272.3333333
?1124.666667
?392
?299.6666667
?581.6666667
?163.3333333
?166.6666667
317
?440.3333333
?186.6666667
?1105.666667
?253.6666667
?177.3333333
?930.6666667
?336
?268
?1423
?364
?296.3333333
?1179.666667
?348.6666667
?227.3333333
?826
?217.3333333
?245.3333333
?181.3333333
?264
?192.6666667
?290
?32.33333333
51.66666667
7194.666667
85
98.66666667
1814.333333
?297.6666667
?178
?501.3333333
595.6666667
1116
3632
995.3333333
710
1525
1310.666667
1465.666667
6104.333333
711
2363
11045.33333
?284.6666667
?161.6666667
?220
?270.6666667
?231.6666667
?286.6666667

Peptide
QDVFCDSKLMSAA
FCDSKLMSAAIKD
SKLMSAAIKDNRA
MSAAIKDNRAVHA
AIKDNRAVHADMG
DNRAVHADMGYWI
AVHADMGYWIESA
ADMGYWIESALND
GYWIESALNDTWK
IESALNDTWKIEK
ALNDTWKIEKASF
DTWKIEKASFIEV
KIEKASFIEVKSC
KASFIEVKSCHWP
FIEVKSCHWPKSH
VKSCHWPKSHTLW
CHWPKSHTLWSNE
PKSHTLWSNEVLE
HTLWSNEVLESEM
WSNEVLESEMIIP
EVLESEMIIPKNF
ESEMIIPKNFAGP
MIIPKNFAGPVSQ
PKNFAGPVSQHNY
FAGPVSQHNYRPG
PVSQHNYRPGYHT
QHNYRPGYHTQTA
YRPGYHTQTAGPW
GYHTQTAGPWHLG
TQTAGPWHLGKLE
AGPWHLGKLEMDF
WHLGKLEMDFDFC
GKLEMDFDFCEGT
EMDFDFCEGTTVV
FDFCEGTTVVVTE
CEGTTVVVTEDCG
TTVVVTEDCGNRG
VVTEDCGNRGPSL
EDCGNRGPSLRTT
GNRGPSLRTTTAS
GPSLRTTTASGKL
LRTTTASGKLITE
TTASGKLITEWCC
SGKLITEWCCRSC
LITEWCCRSCTLP
EWCCRSCTLPPLR
CRSCTLPPLRYRG
CTLPPLRYRGEDG
PPLRYRGEDGCWY
RYRGEDGCWYGME
GEDGCWYGMEIRP
GCWYGMEIRPLKE
YGMEIRPLKEKEE
EIRPLKEKEENLV
PLKEKEENLVNSL
EKEENLVNSLVTA

'ΔFc'IgY
Full'length
Naïve'IgY
?234.6666667
?203.6666667
?1070.333333
?237
?162
?1345.333333
?457.6666667
?259.6666667
?1437.666667
?344.6666667
?264
?927.6666667
?413.6666667
?257
?1046
6872
8417.666667
41015.33333
?263.3333333
?149
?751.6666667
?309.3333333
?157.6666667
?1551.666667
192.3333333
477.3333333
9053.666667
?197
?112.6666667
?359
?32
?30.66666667
1856.666667
?30.66666667
30.66666667
592
?140.6666667
?150.3333333
1284
411
337.6666667
11410.66667
1235.333333
492.3333333
8460
1456
1393
17264.66667
?175
?106
242
?253.6666667
?126.6666667
?545.3333333
?382.3333333
?141.6666667
?508.6666667
?40
?28.33333333
207.6666667
?362
?251.6666667
?489.3333333
?563.3333333
?389.6666667
?759.3333333
?296
?179.3333333
?930
?391.3333333
?198.6666667
?87
?551.3333333
?385
?933.6666667
5405.333333
4268
17690.66667
?416.3333333
?289
?402
750.6666667
419.6666667
8722
?293
?249.6666667
1922.666667
?348.3333333
?219.3333333
?637
449
217.3333333
3956
7395.333333
1068.666667
11936
?146
64.33333333
4276.666667
?233
166
1563
?178
?192.3333333
?839
?383.6666667
?267.3333333
?601.3333333
?288.3333333
?150.6666667
?1346.666667
?343.6666667
?191.6666667
?846.6666667
?439.6666667
?193.6666667
?678.3333333
?540.6666667
?355.6666667
?1100.666667
?546.3333333
?347.3333333
?909
111.6666667
?265
?793.3333333
?217
?203.3333333
117
?294.6666667
?218
?938.3333333
?599
?422.6666667
?966.3333333
?353
?113
?381.3333333
?244
?216
?661.6666667
?228.3333333
?124.3333333
?757.6666667
?201.6666667
?110
?327.3333333
184
339
2556.666667
?340.3333333
?172
?886.6666667
?355.6666667
?188.3333333
?1282.666667
?311
?210.3333333
?1748
?285.6666667
?188.6666667
?1854.666667
?442.6666667
?234.6666667
112
44.66666667
?152.3333333
?549.3333333

Figure 16. Identification of DENV2 NS1 epitopes. Amino acid sequence for NS1 was
used to make 15-mer peptides for microarray slide. Slides were incubated with antiDENV2 IgYΔFc, anti-DENV2 IgY full length, or naïve control IgY. Reactivity is
measured based on a spectrum ranging from no reactivity in black to high reactivity in
red. Values represent MFI-background.
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Determination of anti-DENV IgY neutralizing epitopes
We selected peptides where either anti-DENV2 IgY or IgYΔFc binding to that
spot generated a MFI that was at least 2x greater than the positive control peptide. These
peptides were used in an AminoLink affinity purification column to purify antibodies that
specifically recognize that peptide (peptide specific antibody). To test the neutralization
potential of these peptide specific IgY antibodies we used a PRNT assay. Preliminary
data from these experiments suggest that peptide specific IgY antibodies may be able to
neutralize DENV infection in vitro. Further studies will determine if neutralization is
greater than the polyclonal combined anti-DENV2 IgY and what epitopes have the
greatest neutralization capacity.
Discussion
In this study we demonstrate that anti-DENV2 IgY purified from goose egg yolk
is effective in neutralizing DENV2 D2S10 viral infection both in vitro and in vivo, in the
absence of ADE. Vaccination with the DEVN2 antigen induced a strong humoral
response in the geese, with titers maintained for over six weeks and reaching as high as 1:
3,800,000 (figure). We consistently observed therapeutic efficacy with 2 mg anti-DENV2
IgY administered 24 hours post infection, similar to the 100% therapeutic protection
observed with the MAb E60-N297Q positive control. Our results also indicate some nonspecific protection that may be provided by large amounts of naïve goose IgY as
indicated by both the in vivo challenge data and the epitope mapping. Experiments that
were performed prior to epitope mapping were done using the total combined full length
IgY and IgYΔFc polyclonal antibody population. Further studies will determine the
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neutralization capacity of full length IgY compared to IgYΔFc as well as the
neutralization capacity of the epitope specific affinity purified IgY and IgYΔFc.
At present, there are no licensed therapies or vaccines for the protection of DHF
or DSS, the severe manifestations of DENV infection. The development of a vaccine has
been problematic, in part due to the possible risk of eliciting suboptimal immune
responses that will lead to ADE and severe disease following infection with heterologous
virulent strains. In the absence of an effective vaccine, passive immunotherapy with
neutralizing antibodies may provide an alternative for the treatment of dengue. Our data
suggests that ADE does not occur when anti-DENV2 IgY is administered as a treatment
for dengue. This characteristic is especially advantageous because it does not require any
genetic modification or engineering to prevent enhancement, unlike other non-avian
antibody therapies (214). It has been suggested that ADE results in increased viral load,
increased activation of cytokines, and the activation of complement. All of these
phenomena taking place simultaneous to the immune response to the actual infection
increase the likelihood of vascular leakage and tissue damage. When tissue is damaged
and the vasculature inadequate, the recruitment of immune mediators is also occurring at
these organ sites. This massive increase in cytokines actually becomes detrimental to the
patient and may hamper the clearance of the virus. Likewise, activation of the immune
system may remain high after viral clearance. The combined immune response to DENV,
specifically during heterotypic secondary infections elucidates the need to develop
therapeutics that will not induce ADE, such as anti-DENV2 IgY.
Humanized anti-DENV MAbs obtained from mice or non-human primates have
been produced to treat dengue, but functionally the majority of these antibodies are
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weakly neutralizing and serotype cross reactive (188, 206, 216). Potently neutralizing
human MAbs are rare indicating that only a small fraction of the total antibody response
during natural infection is responsible for virus neutralization. We have done extensive
epitope mapping of three complete DENV proteins; E protein, PrM protein, NS1, and
NS3. Our results suggest that naïve IgY and anti-DENV2 IgY recognize similar epitopes,
but anti-DENV2 IgY also recognizes unique epitopes. The majority of the unique
epitopes were located within the E protein, with some located in the NS3 protein. These
data are consistent with the current literature suggesting that the most neutralizing
epitopes are located within the E protein. In contrast, the NS3 epitopes presented are
uncharacteristic and may be potential neutralizing epitopes that have yet to be exploited
by other research groups. It is important to note that all of the unique anti-DENV2 IgY
epitopes, both full length IgY and IgYΔFc are epitopes that have yet to be published as
neutralizing epitopes for any mammalian or murine MAbs. This confirms that IgY
recognizes different DENV2 epitopes than IgG, and therefore the antibody population
generated in geese is different from what would be generated for production of human
anti-DENV MAbs.
Conclusions
Our results suggest that anti-DENV2 IgY is capable of neutralizing but not
enhancing a DENV2 infection. The anti-DENV2 IgY administered to mice post lethal
challenge with D2S10 is protective. We have confirmed that the antibody repertoire
generated against DENV in geese is different from what occurs in mammals, and thus
provides an increase in potential viral neutralization. Future research will focus on
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characterizing the neutralization and therapeutic capacity of the affinity purified epitope
specific anti-DENV2 IgY.

!

96!

!

CHAPTER V
DISCUSSION
The development of bioavailable, passive immunotherapies to treat infectious
diseases remains an elusive goal. In recent years, passive immunization with avian
derived antibodies has emerged as an attractive alternative to mammalian derived
antibodies to treat disease. Most of the polyclonal antibodies used in passive therapeutics
are of human origin (4). In order to obtain sufficient antibody titers, pre-screened
volunteer human donors are generally immunized with the antigen, and their plasma is
then collected. Unfortunately, there are substantial restrictions to this method including
the limitations to the types of vaccines used, the number of immunizations permitted, the
adjuvant used, and the amount of plasma that can be collected (7). Furthermore,
humanized or human derived antibodies are highly susceptible to unwanted interactions
with conserved proteins, which in turn leads to unwanted immune mediated pathologies
(9). In addition, human-derived antibodies pool are also potentially contaminated with
other unwanted infectious agents, putting the recipient of the immunotherapy at risk of
potentially life threatening infections. The development of unconventional methods of
generating antibodies that are not only suitable for use as therapeutics but also cost and
quantity efficient is an area of active research.
IgY, the major serum immunoglobulin in birds, is transferred from the serum to
the egg yolk during embryonic development. The natural deposition of IgY into the egg
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yolks of immunized birds provides both an excellent source of polyclonal antibodies but
also facilitates a less invasive technique for collecting these antibodies (27, 44, 9).
In addition, the sustained high titers of IgY in immunized birds provide a long-term
supply of substantial amounts of antibody (9).
In an attempt to increase the potential application of IgY therapeutics, one of our
research goals was to determine the bioavailability of IgY following oral administration.
As stated above, there are currently several disease agents that have been utilized in the
production of antigen specific IgY for passive oral therapeutics. For the first time, our
research suggests that IgY is bioavailable as soon as 24 hours post oral administration,
and under specific biochemical conditions remains in the serum for up to 7 days. These
data suggest that IgY is able to cross the epithelial barrier in the intestine and potentially
exert its effects outside of the GI tract. Although the ability of orally administered IgY to
provide protection against disease agents remains to be determined, these data provide
evidence for such possibilities.
There are several physiological, physiochemical, and biopharmaceutical factors
that influence the bioavailability of drugs. The mechanism as to how or why IgY is able
to seroconvert post oral administration is unknown and under investigation in our lab.
One possibility is that IgY is binding to unspecified receptors in the gut facilitating its
translocation. It is important to recognize however that the delivery of therapeutics orally,
even in the absence of a known mechanism of seroconversion, has many advantages.
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Oral therapeutics do not require trained medical professionals for administration, and also
do not require additional medical equipment such as sterile needles and syringes. One
would argue that this would facilitate better compliance if patients were only required to
take an oral medication instead of being injected. Furthermore, oral IgY would be good
candidate therapeutics for use in areas where other administration routes are difficult to
implement due to a lack of economic and healthcare development.
One organism of interest for the development of antigen specific IgY is P.
falciparum, the causative agent of falciparum malaria, and more specifically CM. The
current treatment protocol for CM is the administration of combination antimalarial
drugs, particularly those including artemisinin derivatives. Unfortunately the introduction
of drug resistant Plasmodium strains has facilitated the need for new drug and therapeutic
candidates. In this study we demonstrate that anti-malaria and anti-MSP-1specific IgY is
able to increase the time to death following the induction of CM in mice, possibly
allowing for the introduction of other antimalarial drugs. We also show that IgY
treatment on days 2 and 4 post infection decreases parasitemia. These data suggest that
malaria specific IgY may be a candidate therapeutic for the use in combination therapies.
Further research is being directed at determining what other antimalarial drugs and
formulations of IgY will offer optimal protection.
A second organism of interest for the development of antigen specific IgY is
DENV. At present there are no approved vaccines for DENV, due in large part to the
difficulty in providing cross-reactive protection for all DENV serotypes. In this study we
employ a novel approach to treating DENV induced disease. The advantage of antiDENV IgY for the treatment of DENV is not only the ability to provide therapeutic
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protection, but protection in the absence of ADE. ADE has been suggested to be a
leading cause of the severe DHF and DSS seen during secondary heterotypic infection;
therefore utilizing an antibody therapy that provides protection but does not enhance
infection or stimulate the immune system to dangerous levels is promising. Another
advantage of IgY therapy is that the distinction between birds and mammals allows IgY
to target epitopes that are non-immunogenic in mammals and possibly cross protective
epitopes that will likely not undergo selective pressure to change as rapidly over time.
IgY also has the potential to be used in areas where vaccination to such disease is
not a feasible option. It takes years of research and development to move a vaccine into
the market, and is a costly endeavor. IgY has the potential to be developed quickly and
efficiently and thus could provide more on demand protection, specifically in situations
where the onset of infectious disease in a defined area is very rapid. In some cases where
vaccinating a population is difficult, the therapeutic administration of IgY could still
provide protection for those individuals.
The detailed mechanisms as to how antigen specific IgY (IgY and IgYΔFc) is
able to neutralize and clear these infectious particles in the mammalian system remains to
be elucidated and is an area of active research in our lab. Furthermore, determining what
receptor(s) IgY uses in the mammal, and the downstream effects of receptor activation
will allow for a better understating of how IgY works in the absence of enhancing an
immune response. With these data we will be able to better modify, and further customize
IgY therapeutics to offer optimal protection.
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